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                                                   INTRODUCTION    
Enteroviruses belong to the family Picornaviridae and genus Enterovirus. This 
family includes positive-sense single stranded RNA viruses associated with a 
wide range of human and mammalian diseases. They are named enteroviruses 
because of their major route of transmission by the faecal-oral route and they 
reside and multiply in the gastrointestinal tract. They are major human 
pathogens and are associated with a broad spectrum of clinical features 
including acute respiratory illness, aseptic meningitis, meningo-encephalitis, 
myocarditis, hand, foot and mouth disease, acute haemorrhagic conjunctivitis, 
neonatal multi-organ failure and acute flaccid paralysis (1). Although most of 
the enterovirus infections commonly seen are relatively mild and result in 
complete recovery of the patient, these viruses can also cause severe and 
sometimes fatal illnesses such as meningitis, encephalitis, myocarditis, neonatal 
sepsis, and polio (2). The history of enteroviruses (EVs) is almost the history of 
poliovirus (PV). With control of poliovirus infections in most parts of the world 
through the efforts of the World Health Organization, now the attention has 
turned to the non-polio enterovirus infections, mainly their clinical 
manifestations, complications, diagnosis, and management (3).   
The earlier classification of enteroviruses divided them into Polioviruses, 
Coxsackieviruses, Echoviruses and other Enteroviruses. Enteroviruses are 
recently classified into four Human enterovirus (HEV) species, designated as 
Human enterovirus (HEV)-A,B,C,D, based on homology within the RNA 
coding region for capsid protein,VP1, which contains the major neutralization 
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target (4). Coxsackieviruses (group A) were first isolated during poliomyelitis 
outbreaks in 1947 from the faeces of paralyzed children in Coxsackie, New 
York. These isolates were obtained by inoculation of suckling mice, the 
pathogenicity in mice clearly differentiating these viruses from PV. In the 
following year, the first coxsackievirus (CV) group B was isolated from cases 
of aseptic meningitis. The original CV group A (CVA) isolates produced 
myositis with flaccid hind limb paralysis in new born mice, whereas the 
coxsackieviruses group B (CVB) produced a spastic paralysis and generalized 
infection in new born mice, with myositis and involvement of the brain, 
pancreas, heart, and brown fat. In 1951, echoviruses were first isolated from the 
stool of asymptomatic individuals. Echoviruses received their name because 
they were enteric isolates, cytopathogenic in tissue culture, isolated from 
humans, and orphans (i.e., unassociated with a known clinical disease). 
Enteroviral infections can often be mistaken as bacterial or other viral infections 
and lead to unnecessary treatment, procedures, and diagnostic tests (2). 
Although the exact identification of a serotype may not be necessary for the 
clinician, the exclusion of bacterial infection is very important to avoid 
unnecessary administration of antibiotics and diagnostic tests. With the 
advances in molecular methods, especially polymerase chain reaction (PCR) 
technology in accurately identifying enteroviruses in patient samples as well as 
the recent development of new antiviral therapies, severe enterovirus infections 
are being diagnosed and treated in the early stage itself with better prognostic 
outcomes (3). Outbreaks of disease associated with a single serotype of 
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enterovirus such as hand foot and mouth disease, caused by enterovirus 71, are 
often reported and pose a major public health problem (5). Only a few serotypes 
of enteroviruses cause disease each year within a community, with some of 
these serotypes producing illness more frequently than others. Although some 
of the enteroviruses infect certain tissues preferentially, these tissue tropisms 
are neither very unique to the virus nor specific to the infected tissue even (3).  
The isolation of the virus by cell culture is considered to be the gold standard 
for the diagnosis of enterovirus. However, due to the progress in molecular 
techniques and introduction of advanced molecular  methods like polymerase 
chain reaction, the diagnosis of enterovirus infections now largely depends on 
the amplification of the most conserved region of Human enteroviruses, the 5‘ 
untranslated region (6). These assays are more sensitive than the isolation and 
demonstration of the virus by cell culture. Usually, it is sufficient to know that 
the virus belongs to the genus Enterovirus, from a clinical point of view. 
However, for the further epidemiological analysis, molecular typing of the virus 
has to be done, mainly by partial sequencing of different variable regions of the 
genome of the virus (6).  
Since enteroviruses cause major outbreaks in the community, it has a large 
impact on the public health. Recurrence of known pathogenic strains and the 
emergence of new strains should be anticipated (7). Hence it is essential to have 
a continuous surveillance of various circulating strains of enteroviruses. New 
rapid molecular diagnostic techniques should be utilized to recognize 
enteroviral diseases and to identify the strains causing the disease.  
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Even though there are several antiviral drugs against various viral diseases, 
there are no approved antivirals for the treatment of diseases produced by 
enteroviruses. Since enterovirus diseases cause high morbidity and serious 
consequences after the infection, there is an urgent need for the development of 
antiviral drugs against enteroviruses.   
This study aims to determine the molecular types of enteroviruses causing hand, 
foot and mouth disease, myocarditis, aseptic meningitis and acute haemorrhagic 
conjunctivitis. As there is very limited published literature on prevalent 
molecular types of enteroviruses in south India in these respective diseases, this 
study will add information to the current knowledge.  
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                                             AIM AND OBJECTIVES  
AIM 
To estimate the molecular and sero-epidemiology of enteroviruses in some 
clinically associated diseases. 
 
OBJECTIVES 
1. To compare two real time RT-PCRs amplifying the 5‘UTR region of the 
enteroviruses. 
2. To standardize a conventional PCR for sequencing of VP1-2C region of 
enterovirus genome to determine the molecular types causing some clinically 
associated diseases. 
3. To estimate the IgM seroprevalence of Coxsackievirus in patients with some 
clinically associated diseases. 
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                               REVIEW OF LITERATURE  
    1. Enteroviruses  
Enteroviruses are members of Picornaviridae family, and include Polioviruses 
and other non-polio enteroviruses like coxsackieviruses and echoviruses. The 
most common viruses causing human infections are rhinoviruses. The second 
most common viral infections in humans are caused by non-polio enteroviruses. 
After the elimination of polioviruses from the western hemisphere, non-polio 
viruses have gained attention. There are more than 100 different non-polio 
enteroviruses known to cause human infections. Enteroviral infections are more 
common in infants, children and adolescents than in adults.                      
    2. Properties of enteroviruses  
    2.1. Taxonomy and classification 
Enterovirus is a genus belonging to the family Picornaviridae, a family of small 
non-enveloped viruses containing positive sense RNA genome. The other 
genera in Picornaviridae family are Aphthoviruses, Cardioviruses, 
Hepatoviruses and Rhinoviruses. Genera are defined mainly on the basis of 
physicochemical properties, such as virion density and acid sensitivity (6). 
Serologically distinct enteroviruses were originally distributed into four groups 
based on their different effects in tissue culture and patterns of disease in 
experimentally infected animals: polioviruses (causative agents of poliomyelitis 
in humans and non-human primates), coxsackie A viruses (associated with 
herpangina, human central nervous system disease, and causing flaccid 
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paralysis in suckling mice), coxsackie B viruses (associated with human central 
nervous system and cardiac disease, and causing spastic paralysis in suckling 
mice), and the echoviruses (nonpathogenic in mice, and initially not found to be 
linked to human disease) (7). Coxsackieviruses (group A) were first non-polio 
enteroviruses, isolated by Dalldorf & Sickles, during a poliomyelitis epidemic 
in 1947 from the faeces of paralyzed children in Coxsackie, New York.  These 
isolates were obtained by inoculation of suckling mice, with suspensions made 
from the faeces of children suffering from paralysis (8). The pathogenicity in 
mice clearly differentiated these viruses from PV. In the following year, the first 
coxsackievirus (CV) group B was isolated and recognized as a cause of the non-
paralytic poliomyelitis syndrome, i.e., aseptic meningitis (9). The original CV 
group A (CVA) isolates produced myositis with flaccid hind limb paralysis in 
suckling mice, whereas the coxsackieviruses group B (CVB) produced a spastic 
paralysis and generalized infection in suckling mice, with myositis and 
involvement of the brain, pancreas, heart, and brown fat (10).  Twenty-three 
CVA serotypes [1-22 and 24, CAV-23 was reclassified as echovirus (EV) 9] 
and six CVB serotypes (1-6) have been recognized (6).   
Echoviruses were accidentally isolated from stool samples, during 
epidemiological studies of poliovirus. They were not pathogenic to 
experimental animals even though cytopathic effects were produced in tissue 
culture (Robbins et al., 1951). The name echovirus was chosen because their 
association with human disease was unknown, at the time of their discovery 
(ECHO: enteric, cytopathogenic, human, orphan – unassociated with a known 
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clinical disease).  Echoviruses form the largest enterovirus subgroup. It consists 
of serotypes 1-7, 9, 11-27 and 29-33 (types 1 and 8 represent the same serotype, 
type 10 was shown to be a reovirus, type 28 was found to be a rhinovirus and 
EV-34 was shown to be a variant of CAV-24) (6). After this period of rapid 
growth in the number of enteroviruses, there were several decades where new 
enteroviruses were rarely identified. This changed with the introduction of 
molecular detection methods, and the last 15 years have seen a rapid expansion 
in the number of recognized enteroviruses. This period of discovery is still in 
progress (10). Enteroviruses are recently classified into 4 human enterovirus 
(HEV) species, designated as Human enterovirus (HEV)-A, B, C, D, based on 
homology within the RNA coding region for the capsid protein, VP1, which 
contains the major neutralization target (4). Newly discovered enteroviruses are 
now assigned sequential numbers. 
Enterovirus species                              Types 
Human enterovirus A Human coxsackievirus A2-8, 10, 12, 14, 16 
Human enterovirus 71, 76, 89-92, 114,119 
Human enterovirus B Human coxsackievirus A9, B1-6 
Human echovirus 1-9, 11-21, 24-27, 29-33 
Human enterovirus 69, 73-75, 77-88, 93, 97, 98, 100, 
101, 106, 107, 110 
Human enterovirus C Human poliovirus 1-3 
Human coxsackievirus A1,11, 13, 17, 19-22, 24 
Human enterovirus 95, 96, 99, 102, 104, 105, 109, 113, 
116, 117, 118 
Human enterovirus D Human enterovirus 68, 70, 94, 111 
   Table 1: Current molecular classification of enteroviruses  (11) 
    2.2. Structure of enteroviruses 
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Picornavirus virions are spherical, with a diameter of about 22-30 nm. The 
particles consist of a protein shell surrounding the naked RNA genome. The 
virus particles do not have a lipid envelope, and their infectivity is insensitive to 
organic solvents. The enterovirus capsid is made up of 60 identical building 
units, each containing one copy of the four structural proteins VP1-VP4, 
arranged around axes of five-, three-, and twofold symmetry. The folding 
pattern of polypeptides VP1-VP3 is similar, resulting in an eight-stranded 
antiparallel β-barrel structure (6). One copy of each of the structural proteins 
form a protomer, and 5 protomers form a pentamer. There are 12 identical 
pentamers in an icosahedral capsid. The shell is formed by VP1 to VP3, and 
VP4 lies on its inner surface (11). 
 
Figure 1: Structural organization of enterovirus (Adapted from Reuckert 
et al., 1996) 
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     2.3. Genome of enteroviruses 
The genome of enteroviruses is a single stranded, positive sense RNA with a 
single open-reading-frame (ORF) of approximately 7400 nucleotides (11). The 
viral RNA is infectious in nature since it is translated on entry into the host cell 
to synthesize all the viral proteins which are essential for viral replication (10). 
Enterovirus genomic RNA has a unique structure, because, it is covalently 
linked at the 5‘ end to a protein called VPg (virion protein, genome linked). The 
viral genome is flanked by 5'- and 3‘ untranslated regions (UTRs) which are 
necessary for the replication of viral RNA and its expression. The   5' 
noncoding regions of enteroviruses are long (0.5 to 1.5 kb) and it is highly 
structured. This region has specific sequences that are needed to control genome 
replication and translation. The 5‘-UTR of the genome has an internal 
ribosomal entry site (IRES) that helps in the binding of 40S ribosomal subunit 
for the initiation of mRNA translation. The 3‘ noncoding region of 
enteroviruses is short, ranging in length from 40 to 330 nucleotides. A 
polyadenylated tail (poly A tract) of variable length is attached to the 3‘ end of 
the genome (10). Viral RNA becomes non-infectious if the poly (A) tract is 
removed from the 3‘ end of the genome. The ORF encodes a polyprotein which 
is composed of 3 protein precursors: P1, P2, and P3. The P1 polyprotein 
precursor is processed into 4 viral capsid proteins, VP1 to VP4, while P2 and P3 
are precursors of proteins involved in protein processing and genome 
replication. The seven non-structural proteins are 2A, 2B, 2C, 3A, 3B, 3C, and 
3D. Cleavage is carried out by virus encoded Proteinases (12). These seven 
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non-structural proteins have various roles in processes such as viral replication, 
viral pathogenesis, and immune evasion in the host (13). 
 
Figure 2: Genomic organization of enteroviruses and the cleavage of 
polyprotein (Adapted from Nasri et al., 2007) (14).  
    2.4. Replication of enteroviruses 
Replication of enteroviruses occurs in the host cell cytoplasm. The initial event 
in infection is attachment of the virus to receptor sites on the cellular plasma 
membrane. The surface receptors are different for different enteroviruses. 
However, there is sharing of receptors between some enteroviruses. The 
interaction with the cellular receptor brings about some conformational changes 
in the capsid structure, which leads to uncoating and release of the RNA 
genome into the cytoplasm of host cell. This genomic RNA is of positive 
polarity and is approximately 7500 nucleotides in length. Soon after the entry 
the enteroviruses take over the synthetic machinery of the host cell and both 
protein and RNA synthesis in the host cell is inhibited by the enzyme 2A 
protease. However, there will be selective and efficient translation of viral 
mRNA.  A small (22 amino acids) virally encoded protein, VPg, gets linked 
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covalently to the 5‘ end (uridine) of the viral RNA. After getting released into 
the cytoplasm of infected host cells, a host enzyme removes VPg from the 5‘ 
terminus of the viral genome. Following its removal viral RNA acts as an 
mRNA for synthesis of viral protein and then as a template for  synthesis of 
negative stranded RNA (11). Since virus-encoded proteins are required for 
replication, synthesis of the virus polyprotein requires translation of the large 
open reading frame in the genome. This step is initiated by the binding of the 
40S ribosomal subunit to a specific sequence in the viral 5‘-untranslated region, 
termed IRES (internal ribosomal entry site). The polyprotein precursor is 
cleaved into viral proteins essential for genome replication and the production 
of new virus particles. Mainly two viral proteases are responsible for the 
cleavages; 2A and 3C or 3CD. The proteins synthesized by cleavage are the 
viral RNA-dependent RNA polymerase and some accessory proteins required 
for genome replication and mRNA synthesis. The genome replication is carried 
out by the enzyme RNA–dependent RNA polymerase with the aid of some viral 
and host factors. The initial step in genome replication is the synthesis of a 
negative stranded intermediate from the positive stranded RNA. This 
intermediate acts as the template for the synthesis of new genomic RNA-strands 
by the enzyme RNA-dependent RNA polymerase. These processes occur on the 
surface of small membranous vesicles from the endoplasmic reticulum that is 
induced by several virus proteins. Once sufficient capsid proteins are 
synthesized, encapsidation of viral genome begins. The capsid protein precursor 
P1 gets cleaved to produce the first assembly intermediate, the 5S protomer, an 
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immature structural unit. Then five protomers assemble to form pentamers. 
Newly synthesized, positive stranded viral RNA is inserted into these pentamers 
to form the provirion in which the viral capsid protein VP0 is uncleaved. This is 
followed by cleavage of VP0 into VP2 and VP4. The mature virions containing 
the newly synthesized viral genome get released as the cell loses its integrity 
and lyses leading to cytopathic effects. Approximately 10
4– 105 infectious virus 
particles are released from a single infected cell (6).                               
 
Figure 3: Replication cycle of enteroviruses (Adapted from van der Linden 
et al., 2015) (15).                      
    3. Epidemiology and transmission of enterovirus infections 
Most of the enterovirus outbreaks usually occur in summer and fall months, 
even though some sporadic cases occur year-round. Enteroviruses can affect all 
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the age groups, in which the most likely to be affected group is young children. 
A large number of cases are reported from the age group of one to four years 
old. This tendency is proposed to be due to increased reporting of infections 
caused by enteroviruses from this age group and also the lack of cross reacting 
immunity which develop by the repeated exposure to enterovirus infections 
(16). The additional risk factors in developing countries for getting infected 
with enteroviruses are low socio-economic status and overcrowding. 
Transmission of these infections is mainly through faecal-oral route and by 
respiratory secretions to lesser extent (17). But, transmission through water, 
food, blood and blood products are also reported very rarely (18).  
    3.1. Hand foot and mouth disease 
Hand, foot and mouth disease (HFMD) was first reported in New Zealand in 
1957 (19). Coxsackie virus A16 (CVA16) was first identified next year in 1958 
in Canada as a causative agent of HFMD (20). The main etiologic agents of 
HFMD are Enterovirus 71 (EV 71) and Coxsackievirus A16 (CV-A16). 
Sporadic cases as well as large epidemics of this disease occur throughout the 
world. It usually spreads through close personal contact, contaminated objects 
(with secretions) and rarely through respiratory secretions. This infection can 
occur at any climatic condition, but most commonly seen in summer and early 
fall months. From 1997, large epidemics of HFMD caused by enterovirus 71 
have been reported from east and southeast Asia, mostly in children (21). It was 
responsible for massive outbreaks of HFMD in the late 1990s, in Taiwan (1.5 
million cases) and in Malaysia (Sarawak, 2628 cases) (22). In 2012 EV 71 
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caused a large outbreak of HFMD which widely spread over China, affecting 
more than 2 million people and leading to 567 deaths due to various 
complications, especially meningitis and encephalitis. During this outbreak a 
study was conducted in which various clinical samples like stool, CSF and 
serum were collected from 396 patients reported with HFMD, out of which 
60.35 % of patients who are admitted and 88.46 % of patients with severe 
disease were found to be caused by EV 71 (23). In the same year during the 
rainy season in Thailand, more than 40,000 cases of HFMD were reported and 
Coxsackie A6 played a major role in this large outbreak (24). During two 
HFMD outbreaks which occurred between 2005 and 2008, 30 suspected HFMD 
cases reported to the outpatient unit of a tertiary care centre in South India were 
analysed and 17 (57%) cases were confirmed to be caused by Coxsackievirus 
A16 by laboratory tests(25). Since 2012, Coxsackievirus A6 (CV-A6) has been 
found to be a newly emerging pathogen and has rapidly replaced the original 
circulating strains causing HFMD, EV A71 and CV A16, becoming the 
predominant causative agent of HFMD (26). A study was conducted in HFMD 
patients who were admitted in three major hospitals in Vietnam during 2011-
2015, and in 514 out of 2,230 cases CV-A6 was detected (27). This indicates 
the importance of active surveillance for etiological agents of HFMD other than 
EV-71 and CV-A16.  
    3.2. Aseptic meningitis 
Infections of central nervous system with non-polio enteroviruses have a 
significant morbidity in children and adults. Non-polio enteroviruses are 
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considered to be the most common cause of aseptic meningitis which accounts 
for approximately 80 – 92% of all cases of aseptic meningitis in which a 
causative agent is identified (28).  It is the most commonly encountered clinical 
syndrome caused by enteroviruses (2). Although globally enteroviral meningitis 
occurs throughout the year, there is a marked seasonal distribution of the cases, 
with peak incidence in the summer months in temperate countries. Various 
studies done in different parts of the world showed that enteroviruses, especially 
Echoviruses are a major cause of aseptic meningitis particularly in children. The 
following table shows different studies done in aseptic meningitis patients and 
the number of samples in which enterovirus genome was detected. 
Place/year Samples 
collected  
Number of 
positive 
samples  
     % of 
positive
s  
Types 
isolated  
Author  
US/ 
1994-2002 
CSF 47 of 96  48.9% Not 
sequenced  
Michos et al, 
2007 (29) 
Kuwait / 
2007-2010 
CSF 92 of 387 24% Echovirus 
9, 11, 30 
CV B4, B5  
EV 71 
Dalwai et al 
2010 (30) 
Korea / 
2008 
CSF, stool/ 
rectal swab, 
throat swab, 
blood, urine 
513 of 758 68% Echovirus 
1, 6, 7 ,9 , 
16, 30 
CVB1,B3,
A3,A4,A6,
A10 
Kim et al 
2012 (31) 
China/ 
2006-2012 
CSF, throat 
swab, stool 
84 of 437 19.2% Echovirus 
3, 4, 6, 9, 
25, 30 
Tao et al, 
2014 (32) 
India (UP) /                          
2009-2010 
CSF 45 of 204 22.1% Echovirus 
1, 19, 21 
CV B1, B5 
EV 75, 76 
Kumar et al, 
2012 (33) 
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TABLE 2: Prevalence of enteroviruses in aseptic meningitis in studies 
done in different parts of the world                        
Even though enteroviruses are ubiquitous in nature, some specific serotypes 
may be predominantly causing infections in a particular area. But other 
serotypes are introduced periodically to cause epidemics. Hence it is necessary 
to have a continuous epidemiological surveillance for the detection and 
identification of new serotypes or variants of enteroviruses which are 
responsible for the outbreaks (34).                        
    3.3. Myocarditis                       
Coxsackie B (CV-B) viruses are known as the most common viral cause of 
myocarditis. The epidemiological data demonstrate that CV-B myocarditis 
occurs mainly during autumn and winter, and young male adults are more 
susceptible than adolescents or adults. A study conducted in Tunisia in 2014 
identified coxsackie virus B-1 as the causative agent in 9 out of 51(17.64%) 
patients with myocarditis (35). In India, in a study conducted in 1990, in thirty 
two patients with acute onset of cardiac symptoms following an episode 
suggestive of viral infection, 11 (34.37%) had Coxsackie viral myocarditis(CV 
B2 and CV B4) (36). There are no further studies published from India 
regarding myocarditis caused by enteroviruses.                               
    3.4. Acute haemorrhagic conjunctivitis 
The first cases of acute haemorrhagic conjunctivitis (AHC) were reported in 
Accra, Ghana, and Singapore during 1969–1970 (37). The most common 
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etiologic agents causing AHC epidemics are enterovirus 70 (EV-70) and 
coxsackievirus A24 (CV-A24) (38). Transmission is usually by direct close 
person-to-person contact or indirectly through fomites or unsafe water in 
recreational water facilities (39). During an outbreak of AHC in Melaka, 
Malaysia, between June 2002 and October 2003, which has affected more than 
10,000 people, conjunctival swabs were collected from 86 patients and 59 
(68.6%) turned out to be positive for coxsackievirus A24 (40). In another large 
nationwide outbreak of AHC affecting more than 300,000 people over 3 
months, in Thailand, coxsackievirus A24 variant was identified in 70.59 % 
(84/119) of the samples (41). The outbreaks of AHC in India generally occur in 
hot and humid climates, during the months of August and September. In 
Maharashtra and Gujarat states of India an outbreak of AHC occurred in 
August-September 2003, in which eye swabs were collected from 11 
conjunctivitis patients and all of them were found to be caused by 
coxsackievirus A24 (42).  
    4. Pathogenesis of enterovirus infections  
Enteroviruses are cytopathic in nature. Most of the enterovirus associated 
diseases are due to tissue-specific cell destruction, but some manifestation like 
exanthemas and myocarditis are thought be the result of host immune response 
to the viral infection. For most of the enteroviral disease manifestations the 
mechanisms are not well characterized (43). The incubation period for most of 
the enterovirus infections ranges from 3 to 10 days. Enteroviruses are acquired 
through faeal-oral route and/or respiratory route, and rarely through 
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transplacental route (44). Their primary replication happens in oro-pharyngeal 
and intestinal epithelial cells. Sometimes the replication also occurs in 
nasopharynx from where the virus spread to the upper respiratory tract. Since 
the virus has a predilection for lymphoid tissue, it enters the lymphoid tissue of 
small intestine and upper respiratory tract like, Peyer‘s patches in the lamina 
propria, mesenteric lymph nodes, tonsils and cervical lymph nodes  where 
significant viral replication occurs (45). Then the virus enters the blood stream, 
which results in a minor primary viremia. Through the blood stream it enters 
various target organs like central nervous system (CNS), heart, liver, pancreas, 
adrenal glands, skin and mucous membranes. The secondary infection of CNS 
causes meningitis and encephalitis and that of heart causes myocarditis. 
Extensive replication of virus occurs in these target organs which then get 
released into blood stream causing a major secondary viremia and leads to 
dissemination of virus. CNS involvement is mainly through viremia and some 
enteroviruses have increased neurotropism (46).  
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Figure 4: Pathogenesis of enterovirus infection (Adapted from Noor et al., 
2016) (47).  (CNS=central nervous system, GI=gastrointestinal, 
PCR=polymerase chain reaction) 
The antibody response to enterovirus infections mainly includes an early IgM 
response at 7 to 10 days, which is followed by a rise in IgG and intestinal IgA 
antibodies. There is a serotype specific relative immunity to re-infection. But, if 
re-infection occurs, the symptoms will be minimal or it may be a subclinical 
infection.                        
    5. Clinical features  
Enteroviruses are one of the most common groups of viruses causing disease in 
humans. Even though most enterovirus infections are asymptomatic they can 
produce a wide range of clinically distinct syndromes, affecting central nervous 
system (CNS), cardiac and skeletal muscle, skin, pancreas and mucous 
membranes (48). The clinical syndromes caused by enteroviruses include 
undifferentiated febrile illness, neonatal infections, respiratory infections, 
aseptic meningitis, encephalitis, myocarditis, hand foot and mouth disease, 
acute haemorrhagic conjunctivitis, herpangina, epidemic pleurodynia etc (49). 
    5.1. Hand foot and mouth disease 
Hand, foot and mouth disease is a very common contagious disease usually 
affecting children under the age of 5 years. However, it can spread to older 
children and adults also. The clinical symptoms of this disease are typically 
mild and self-limiting. Very rarely patients may also develop severe 
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neurological complications such as encephalomyelitis, aseptic meningitis and 
acute flaccid paralysis and can even lead to death (50). Neurological 
complications are mostly associated with disease caused by Enterovirus 71. 
Usually the disease starts with a prodrome of mild fever, malaise, sore throat, 
headache, and loss of appetite which is followed by sores or ulcers in mouth 
and papulo-vesicular rashes on hands, feet and buttocks (51). It can also affect 
tongue producing lesions suggestive of aphthous stomatitis and some patients 
may have involvement of palate, uvula and anterior tonsillar pillars. These 
lesions usually resolve within one week (3). These oral lesions can be 
misdiagnosed easily as aphthous ulcers, varicella or herpangina. However, in 
varicella the skin lesions are more concentrated on trunk and rarely seen on 
palms and soles. Oral lesions are also very rare in varicella. Herpangina is a 
viral infection caused by coxsackievirus A. This usually presents with similar 
oral lesions, but are more extensive involving tonsils, soft palate and mucosa of 
posterior pharyngeal wall (52).                        
    5.2. Aseptic meningitis  
The term aseptic meningitis refers to a syndrome characterised by acute onset of 
meningeal symptoms and fever, with CSF pleocytosis without any growth in 
routine bacterial culture. Viral meningitis can occur at any age but is most 
common in young children (53).  Enteroviruses are the most common cause of 
viral meningitis,  which accounts for 80% to 92% of aseptic meningitis cases in 
which a causative agent has been identified (54). The non-polio enteroviruses 
causing aseptic meningitis include echoviruses, coxsackie A and B viruses and 
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other numbered enteroviruses (55). In children, the clinical signs and symptoms 
of enteroviral meningitis are mostly asymptomatic and are similar to those of 
bacterial meningitis or sepsis. The most common presenting symptom is fever, 
which is followed by irritability, lethargy, muscle aches, anorexia, respiratory or 
gastrointestinal symptoms and sometimes otitis media (56). Fever usually 
ranges from 38 to 40
o
C and is often associated with Kernig and Brudzinski 
signs. These symptoms may be preceded for several days by non-specific 
symptoms like low-grade fever, photophobia, rash, nausea, sore throat, and 
cough (11).  In a study done by Wildin S et al., 9% of children with enteroviral 
meningitis had apnoea (57). Some children present with specific symptoms of 
central nervous system disease like neck stiffness and bulging fontanelle. Less 
than 10% of patients may present with seizures (56). The acute illness has good 
prognosis and usually resolves without consequences in 1 week to 10 days even 
though malaise and fatigue may persist for few weeks. However, in some cases 
the infection may progress to symptoms of encephalitis with focal neurologic 
deficit, especially in newborns.  Occasionally transient ataxia and paralysis 
occur. In this case, there may be a poor prognosis which can even lead to death 
due to cardiac failure or liver damage (58). Enterovirus 71 can affect the central 
nervous system in children and can lead to severe damage. This may progress to 
a more severe form and can even result in paresis and brainstem encephalitis 
(41).  
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     5.3. Myocarditis 
Viral myopericarditis involves inflammation of both the heart muscle and the 
serous layer of pericardium. Some enteroviruses have a tropism for heart and 
skeletal muscles (59). Coxsackievirus B is a frequent cause of 
myopericarditis(35) and even can be caused by a combination of coxsackievirus 
A and coxsackievirus B (60).  Myocarditis without pericarditis is typically seen 
in infants, whereas it is usually associated with pericarditis in older children and 
adults. Failure in early diagnosis and inappropriate treatment can lead to 
permanent sequelae and even death (61). Echoviruses may also cause 
myopericarditis in some cases (62). The extent of cardiac involvement is 
usually reflected by the severity of symptoms and varies from mild palpitations 
and chest pain to fatal arrhythmias and congestive heart failure (61). The 
commonest symptoms are chest pains, vertigo, breathing difficulty, general 
weakness, fever etc. Swelling of the hands and feet may also occur in some 
patients. Sometimes, myopericarditis manifests as sudden loss of consciousness, 
which may be associated with abnormal rhythm of heart. At times, breathing 
difficulty may be the presenting symptom in children. Myocarditis can also 
convert into acute myocardial infarction (63). The most common ECHO 
findings of myocarditis are global akinesia, left ventricular dysfunction and left 
ventricular dilatation (64). Even though most of these patients recover 
completely without any complications, some may develop chronic myocarditis 
which leads to dilated cardiomyopathy and congestive heart failure (65).  
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    5.4. Acute haemorrhagic conjunctivitis 
Acute hemorrhagic conjunctivitis is a highly contagious illness of eyes. This 
disease usually presents after an incubation period of 24 hours. It is 
characterized by a sudden onset of bilateral conjunctivitis which is associated 
with congestion, photophobia, eye discharge and sometimes pain in the eyes 
(66). A prominent feature is the presence of subconjunctival haemorrhages 
which are pinpoint or large. This may or may not be associated with general 
symptoms like fever, headache, malaise etc (67). It usually resolves within 7-10 
days without any permanent sequelae, but very rarely it can cause neurological 
complications, including paralysis (68).  The enteroviruses causing this disease 
are Coxsackievirus A24 (69) and Enterovirus 70 (38).   
    6. Laboratory diagnosis of enterovirus infections 
Enterovirus infections are very common and have diverse clinical 
manifestations. These infections usually mimic bacterial infections. Hence, 
timely confirmation of the clinical diagnosis is necessary in reducing the length 
of hospital stay, avoiding unnecessary administration of antibiotics and various 
diagnostic testing performed to exclude other conditions and also in minimizing 
the risk of complications. In addition to this it also helps the health care 
providers to respond, especially to outbreaks. Viral culture and isolation is 
considered as the gold standard for diagnosis of enterovirus infections (70). 
However, various studies in the last decade have come to a conclusion that 
molecular diagnosis based on the amplification of the nucleic acid using 
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polymerase chain reaction (PCR) is more useful in the diagnosis of enterovirus 
infections. PCR is more sensitive and provides a rapid and more specific 
diagnosis when compared to viral culture.    
Samples for laboratory diagnosis have to be collected according to the clinical 
manifestations. Samples collected may be throat, rectal and conjunctival swabs, 
CSF, serum, and fluid from vesicle. The sensitivity and specificity of the test 
done can vary according to the sample collected. Detection of the virus from 
samples collected from sterile sites such as CSF, serum and vesicular fluid is 
more reliable than from samples collected from unsterile sites like throat and 
rectum, since in unsterile site, it may be a coincidental carriage and it may result 
in false positive result.  
     6.1. Viral culture and isolation 
Isolation of the virus by cell culture is the most reliable method for the 
diagnosis of enterovirus infections and it is the ―gold standard‖ (71). Poliovirus 
was easily cultivable in various mammalian cell lines. L20B cell line was used 
in earlier times for the primary isolation of polioviruses from clinical samples 
(72). Several human and non-human primate cell lines can be used, which 
includes primary monkey (African green, cynomolgus, or rhesus) kidney cells 
(PMK) and human diploid fibroblast cells like MRC-5 or WI-38 (1). Other cell 
types which can be used are continuous human heteroploid cells like HEp-2 and 
HeLa, human fetal kidney, human rhabdomyosarcoma (RD) and chicken 
embryo and also BGM line from African green monkey kidney cells (56). The 
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sensitivity of cell culture is highly dependent on the type and quality of 
specimen, the timing of its collection and its storage at appropriate temperature 
before reaching the laboratory. There is no single cell culture which is suitable 
to recover all the commonly infecting human enteroviruses. The use of more 
than one cell types help in the recovery of more number of serotypes. The yield 
and speed of recovery of virus from clinical specimens can be increased 
significantly by the combined use of three or four cell culture systems. Animal 
inoculation is required for the isolation of many serotypes of group A 
coxsackieviruses. Some serotypes (A7 and A9) grow well in PMK cells. RD 
cells are useful for the recovery of echoviruses and some serotypes of group A 
coxsackieviruses (73). A continuous African green monkey kidney cell line, 
BGM, helps in speedy and efficient recovery of Group B coxsackieviruses (74). 
In spite of the availability of different cell lines for the routine culture of 
enteroviruses, some serotypes of enteroviruses do not grow in cell culture (75). 
Of the specimens collected from patients with various characteristic enterovirus 
infections, 25-35% give a negative result from cell culture due to various 
reasons like intrinsic insensitivity of these cell lines to the virus, neutralization 
of the virus by antibodies in situ, inadequate collection and inappropriate 
handling and processing of the samples (76).  
The identification of an isolate in cell culture as an enterovirus is based on 
characteristic cytopathic effect (CPE) produced along with other information 
like source of the sample, and clinical history of the patient. The identification 
of the specific serotype of non-polio enterovirus can be done by virus 
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neutralization using serotype-specific antisera or intersecting virus antiserum 
pools (77).  
    6.2. Animal inoculation 
The method of choice for the primary isolation of group A coxsackieviruses is 
the inoculation of the sample into suckling mice since it is difficult to isolate 
them in cell culture. Although group B coxsackieviruses and other enteroviruses 
also can be isolated in suckling mice, it is easier to grow and isolate them in cell 
culture. Group A coxsackieviruses produce generalized myositis and flaccid 
paralysis whereas group B viruses produce focal myositis and spastic paralysis. 
Group B coxsackieviruses also affect other organs like heart, brain, liver, 
pancreas and skeletal muscles and also produce typical lesions in brown fat 
(interscapular fat pad) (78). This technique is rarely used nowadays because of 
the practical difficulties. 
    6.3. Serology 
Serological diagnosis of enterovirus infections is highly complicated due to the 
presence of large number of serotypes, occurrence of anamnestic reactions, 
heterotypic antibody responses and the lack of a common antigen, the antibody 
to which uniformly cross reacts with all the serotypes. Appropriately timed 
paired sera are required to demonstrate a significant rise in antibody titre which 
is diagnostic. This also is a limiting factor for using serological testing for the 
diagnosis of enterovirus infections. The demonstration of a high titre of 
enterovirus-specific IgM antibody in a single serum sample also indicates a 
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current antigenic stimulus and gives an evidence for a recent infection. 
However, the interpretation of the results must be done very carefully, since it is 
necessary to know the background levels of IgM antibody in the general 
population. It may be high especially during epidemic seasons.   
    6.4. Typing of enteroviruses. 
Enteroviruses are genetically diverse due to the variability in their genome. 
Enterovirus typing is needed primarily to provide information about the 
relationship between viruses, to identify the types of virus associated with 
increased virulence, to find the disease associations of specific enterovirus 
types, for epidemiological investigations and to correlate with the viral 
immunity. The development of new molecular technologies has made the 
molecular typing of enteroviruses simpler, and they have also helped to type the 
viruses which were non-typeable by the conventional method.  
    6.4.a.  Enterovirus serotyping using the conventional method 
Before the development of advanced molecular methods enteroviruses were 
typed by neutralization of the infectivity of the particular virus with serotype-
specific antisera. However, it was clearly impractical to identify all the 
serotypes (more than 100) of enteroviruses by neutralization with reference 
antisera. Therefore, to overcome this inconvenience various intersecting pools 
of antisera containing different combinations of individual antisera have been 
prepared by mixing the equine type-specific hyper-immune sera. In this method 
the isolates of enterovirus were incubated with the each antiserum pool one-by-
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one, and then reinoculated onto a susceptible cell line. It develops a 
neutralization pattern after incubation for several days. These pools are 
designed in such a way that the neutralization pattern will be distinct for each 
serotype of enteroviruses. Finally neutralization with type-specific antiserum 
helps to confirm the serotype (75). The antisera pool called Lim Benyesh-
Melnick (LBM) pool scheme has eight different pools (A to H) of antisera 
containing antisera against 42 different enterovirus serotypes (79). Seven 
additional pools (J to P) are there containing antisera against an additional 19 
CAV serotypes. These can be used to identify the viruses which are non-
typeable using the pools A to H (80). Other than this alternative antisera pools 
developed at National Institute of Public Health and the Environment (RIVM) 
were used, which were able to identify enterovirus types 68 to 71 also (81).  
A number of limitations are there for using intersecting pools for the typing of 
enteroviruses. The limitations are given in the table below. 
Limitations of using intersecting antisera pools for serotyping of 
enteroviruses 
i. The process is time-consuming, tedious and expensive. 
ii. There is only a limited supply of antisera, and WHO advocated that the 
antisera should not be used for every clinical isolate. 
iii. There are ―untypeable‖ enterovirus strains frequently isolated. 
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Table 3: Limitations of using intersecting antisera pools for serotyping of 
enteroviruses (75). 
    Reasons for ―untypeable‖ strains of enteroviruses (14)  
i. The newly emerged serotypes are not included in the intersecting antisera 
pools. 
ii. A mixture of different serotypes in the same sample cannot be neutralized 
by these reagents. Hence, an additional step of cloning is needed to purify the 
mixture.  
iii. These pools cannot neutralize the aggregated viruses.  
iv. The antigenic shift in different strains leads to the emergence of new 
viruses (prime strains) which are not recognized by the antisera pools produced 
many years ago.  
Another method for serological typing of enteroviruses is by using type-specific 
monoclonal antibodies through a rapid indirect immunofluorescence assay (82). 
In this method the specific monoclonal antibody binds to the particular serotype 
and this complex is detected by a fluorescent conjugate. However, the 
development of a complete panel of monoclonal antibodies which is able to 
identify all the enterovirus serotypes is highly expensive and not practical. 
Additionally, this method is not suitable to identify variant serotypes and newly 
emerging serotypes.  
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     6.4.b. Molecular typing of enteroviruses 
The recent advances in molecular biology led to the development of several 
molecular assays based on RT-PCR, followed by nucleic acid hybridization or 
sequencing for the identification of enteroviruses. Before typing it is necessary 
to amplify the viral genome by using a RT-PCR or any other amplification 
method. The amplified product can be typed by either methods not based on 
amplicon sequencing or methods including sequencing of the amplicon.  
Initially, methods which are not based on amplicon sequencing were proposed, 
since they are relatively easy to perform. They include detection and 
identification of the amplicon using restriction fragment length polymorphism 
(RFLP) analysis (83) and hybridization with type specific probes (84). These 
methods targeting the 5‘UTR and VP1 regions were giving good results in 
typing and in differentiating intratypic variants of wild and vaccine strains of 
poliovirus since it has only very limited number of serotypes (85). But these 
methods failed to give consistent results for non-polio enterovirus typing 
because of the following reasons: 
i. Point mutations can modify the restriction sites. 
ii. These studies mainly targeted the 5‘UTR, because it is the most conserved 
region in the enterovirus genome. But, it is not variable enough to discriminate 
between different serotypes. 
This has led to the use methods based on sequencing of the amplicon. It 
includes: 
32 
 
1) A RT-PCR with primers which are sufficiently conserved to bind to the 
genome of most of the serotypes of enteroviruses, but flanking a variable 
region.  
2) The sequencing of amplicons from the RT-PCR. 
3) Comparison of these sequences with the genomic banks accessible through 
internet.  
Phylogenetic analysis of the reference strains of enteroviruses was done which 
showed that sequencing of different parts of the genome can help in typing. 
Typing methods are limited by recombinations occurring in the genome of 
enteroviruses. But, various parts of the capsid region can be used for this 
purpose since recombinations occur in this region in a very low frequency (14).  
Sequencing of VP1 coding region for typing 
The sequencing of VP1-2A (450bp) region was used for typing of enteroviruses 
by Oberste et al in 1999. However, this method was able to identify only 44 out 
of 64 tested prototype strains (86). In 2001, Caro et al., has proposed an 
alternative approach by targeting a long coding region of 1452 bp. They used a 
mixture of three degenerate primer pairs with the sense primers located in the 
distal part of VP1 and antisense primers located in 2C region (VP1-2C) (87). 
This method was able to identify 59 of the 64 prototype strains tested.  
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Advantages of sequencing of VP1-2C region: 
i. VP1 protein is the most exposed among the structural proteins. It constitutes 
the antigenic neutralization sites and has been found to be the most suitable 
region for the molecular typing of enteroviruses.  
ii. Due to the presence of conserved regions, generic antisense primers could 
be selected in the 2C region. 
iii. The amplification of a longer fragment (1452 bp), which includes the non-
structural protein coding region 2A to 2C in addition to that corresponding VP1, 
helps to provide information regarding the viral determinants of virulence and 
pathogenesis. This also helps to determine the correlation between the clinical 
syndrome and the serotype causing it.  
 
    Sequencing of VP4 coding region for typing 
VP4 protein is encoded by a gene positioned between the 5‘UTR and the VP1 
gene of the enterovirus genome. Rotbart et al (2) and Olive et al designed well-
conserved primers in the 5‘UTR and the VP1 gene respectively, which allowed 
amplification of a genome fragment of 753 bp including the whole VP4 gene 
(88). This method was able to identify all the reference strains of enteroviruses 
and 86 clinical isolates were successfully typed into 26 different serotypes. 
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However, the sequencing of VP4 region is less discriminating than that of VP1 
region, due to the greater variability in the gene encoding for VP1 protein (89).  
 
Sequencing of VP2 coding region for typing  
Before the selection of VP1 region for typing, primers to amplify a fragment of 
150 bp located at the 3‘ end of the gene encoding for VP2 protein, were 
designed by Oberste et al (90). But, the region of protein VP2, encoded by the 
part of genome sequenced by these primers located at the interior of the capsid, 
is not discriminant enough for the correct identification of enteroviruses. In 
2007, another set of degenerate primers were designed to amplify a 583 bp 
fragment of the genome which encodes almost the entire VP2 gene, by Nasri et 
al (91). A 368 bp fragment located at the 3‘region of this gene was sequenced 
and was used for typing. This method was able to type all the 116 clinical 
isolates belonging to 36 serotypes. 
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    Sequencing of both the 3’UTR and the VP1 region for typing  
Four primer sets located in the 3‘UTR were used to detect all four species of 
human enteroviruses (HEV-A, HEV-B, HEV-C and HEV-D). This region is 
good for species level clustering of strains as it has a good interspecies 
diversity, but, less intraspecies diversity. After this step, more specific primers 
located in the VP1 region were used for the serotype identification of the 
Figure 5:  
Phylogenetic tree obtained 
from partial sequencing of 
VP2 capsid protein (Adapted 
from Pulli et al., 1995; 
Huttunen et al., 1996) 
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strains. This method is too labor-intensive for routine use. However, this was 
able to identify most of the tested strains (92).  
    Benefits of molecular typing of enteroviruses 
i. The information about the circulating strains in the environment and humans   
    will help in the prevention of transmission and control of outbreaks.  
ii. It helps in differentiation of polio and non-polio enteroviruses. 
iii. Molecular typing is the tool for the identification of new strains and  
     variants. 
iv. It helps to find out the pathological conditions associated with each 
     serotype.                  
    7. Management of enterovirus infections 
Unfortunately, there is no antiviral medication or treatment available 
specifically for the management of enteroviral infections. The best care for 
these infections is provided through appropriate supportive measures. The 
mainstay of care for a viral syndrome caused by enteroviruses is proper fluid 
hydration and antipyretics. 
In severe diseases like neonatal sepsis and meningitis, intravenous immune 
globulin (IGIV) or hyper immune plasma administration has been tried since 
antibodies are key factors to defend the infection caused by enteroviruses (93). 
This was based on various small clinical studies and case reports which 
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suggested improvement in disease symptoms. The IVIG preparations contain 
neutralizing antibodies to enteroviruses in variable amounts. Hence patients 
may experience a rapid clearing of virus from blood and urine. It has been used 
in outbreaks caused by EV-71. However, higher concentrations of antibodies 
specific to the infecting virus are needed to neutralize the virus and to alter the 
course of the disease.  
A number of molecules have been found which are able to bind to the capsid of 
enterovirus particles or to inhibit enterovirus replication by interfering with the 
viral proteins necessary for replication. Some of these have been used in clinical 
trials. Pleconaril {3-[3,5-dimethly-4-[(3-methyl-5-isoxazoly) propyl] phenyl]-5 
(trifluoromethyl)- 1,2,4- oxadiazole} is a viral capsid inhibitor compound which 
has potent broad spectrum activity against enteroviruses (EVs) and rhinoviruses 
(RVs) both in-vitro and in-vivo (94). It has high bioavailability when 
administered orally. It binds to the viral capsid and prevents attachment to the 
host cell, uncoating and subsequent release of the viral RNA into the host cell 
cytoplasm. Various clinical trials have shown that pleconaril has provided 
clinical benefit for patients with common cold caused by enteroviruses and 
rhinoviruses, enteroviral meningitis and severe life-threatening infections in 
populations at risk (95). The US Food and Drug Administration (FDA) declined 
its approval until 2003, due to concerns regarding various drug-drug 
interactions, evolution of resistance to the drug and other concerns. During this 
period it was only used for treatment of myocarditis and aseptic meningitis in 
infants on a compassionate basis.  A lengthy double-blind, placebo-controlled 
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trial of pleconaril was done for the treatment of enterovirus sepsis in neonates 
by Abzug et al in 2016 (96). In this study the number of deaths was less in 
infants treated with pleconaril than in those who received placebo [10/43 (23%) 
Vs 8/18 (44%), p=0.02], but the mortality rates were not significantly different 
in infants with proven enterovirus infection [7/31 (23%) Vs 5/12 (42%), 
p=0.26] (96). Additional studies with a larger sample size are needed to prove 
the efficacy of the drug in viral suppression.  
There are other capsid-binding agents also, like pirodavir and vapendavir with 
antiviral activity against EV 71 (97). However, there is very limited clinical 
experience with these drugs. There are other novel enterovirus specific 
inhibitors also identified. But these agents have not progressed to clinical trials 
due to poor bioavailability, limited antiviral activity and intrinsic resistance to 
these agents in some circulating strains (98). 
The development of antiviral therapy for enteroviruses could be facilitated by 
repurposing some existing medications. For example, the antidepressant 
fluoxetine, the antimalarial drug mefloquine and amiloride, a diuretic exhibit in 
vitro activity against one or two enteroviruses (98).  
8. Prevention  
Based on experience with poliovirus, which was effectively wiped out by 
vaccination, it is assumed that even the disease burden caused by non-polio 
enteroviruses can be reduced by an effective vaccine. But, unfortunately there 
are no effective vaccines available for non-polio enteroviruses.  
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There has been extensive research going on in this area, especially to develop 
vaccines against EV 71. There have been several vaccine candidates for EV 71 
which includes recombinant proteins and synthetic peptides, virus like particles 
(VLPs), live attenuated strains and inactivated whole-virus. High levels of IgG 
antibody specific to EV 71 VP1 can be induced by immunization with EV 71 
VP1 protein expressed in yeast, Escherichia coli or baculovirus system (99). 
VLPs resembling the capsid structure of natural EV 71 virus have been 
produced and purified as potential vaccines and has been proven to be 
immunogenic in newborn mice (100).  DNA vaccines containing VP1 protein of 
EV 71 also have been tried which could elicit production of IgG and 
neutralizing antibodies against VP1 protein of EV 71 (101).  An attenuated 
EV71 genotype A (BrCr) was used to immunize cynomolgus monkey, which 
could induce high titres of neutralizing antibodies against EV 71. These 
antibodies showed cross-reactivity for other genotypes and also conferred 
protection against lethal challenge in the monkey by virulent EV71 genotype 
A (102). Among the various vaccine candidates the preparation of choice is 
inactivated whole-cell vaccine, which provides effective control. Formalin 
inactivated EV 71 strain is capable of eliciting high levels of virus-specific 
antibody with cross-reacting activity and proved to be protective for the 
immunized host, when a lethal challenge with a virulent EV 71 strain was given 
to newborn mice (103). The first vaccine against EV71 was manufactured by 
the Institute of Medical Biology at the Chinese Academy of Medical Sciences 
and was approved by the Food and Drug Administration (FDA) in December 
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2015. Another EV71 vaccine manufactured by Sinovac Biotech was approved 
by Chinese FDA in January 2016 (104). More follow ups are needed to develop 
effective vaccines against non-polio enteroviruses.  
The primary defence against the transmission of enteroviral infections is 
maintenance of good hygiene, particularly hand washing, to prevent the 
transmission of the virus from person-to-person through faeco-oral route. The 
prevention of transmission of enteroviral infections is important especially 
within families, in pre-school and school settings, hospital nurseries and nursing 
homes (105). Pregnant women near term are advised to avoid contact with 
individuals having infections likely to be caused by enteroviruses.  
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                                            MATERIALS AND METHODS 
1. Study design 
This is a prospective observational study conducted at the Department of Clinical 
Virology, Christian Medical College and Hospital, Vellore. Different clinical samples 
like vesicular swab, CSF, serum and/or pericardial fluid and conjunctival swab were 
collected from clinically suspected cases of hand foot and mouth disease (HFMD), 
aseptic meningitis, myocarditis and acute haemorrhagic conjunctivitis (AHC) 
respectively. These samples were tested for enterovirus by using two real time 
screening RT-PCRs. The samples which were positive for enterovirus were  amplified 
using a conventional PCR which was followed by sequencing and the molecular types 
were determined by BLAST analysis. An ELISA was used to estimate the sero-
prevalence of coxsackievirus.  
2. Ethics approval 
The approval for the study was obtained from the Institutional Review Board, 
Christian Medical College, Vellore (IRB Min No: 10424 dated 05.12.2016).  
3. Funding: The study was funded by Internal Fluid Research Grant and Virology 
special fund. 
4. Study duration : The study was conducted over a period of 16 months from April 
2017 to July 2018. 
5. Sample size calculation 
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The required sample size to determine the prevalence of Coxsackie viruses in aseptic 
meningitis, myocarditis, hand, foot and mouth disease and acute haemorrhagic 
conjunctivitis was found to be 278(≈300) samples with 3% precision and 95% 
confidence limits. Since it is a pilot study, 150 will be the sample size. 
 
 
                              Single Proportion - Absolute Precision  
 
Expected Proportion  0.07  0.07  0.07  0.07  0.07  0.07  
Precision (%)  3  2.5  2  3.5  4  5  
Desired confidence level 
(1- alpha) %  
95  95  95  95  95  95  
Required sample size  278  400  625  204  156  100  
The anticipated prevalence was taken from the table shown below from studies done in 
India and elsewhere.  
Table 4: prevalence of coxsackievirus in India and elsewhere. 
     
        Date  
 
   Place  
 
     Year  
 
% of positivity for  
Coxsackie virus  
among samples  
Hand foot and 
mouth disease 
China  
China 
India  
2011-2014 
2012 
2012 
36.36% 
19.6% 
43.82% 
Aseptic meningitis  China 
India  
2009 
2012 
37.20% 
7.14% 
Myocarditis  Tunisia  
Sudan  
2014 
2015 
27.45% 
68.9% 
Acute 
haemorrhagic 
conjunctivitis 
India  
China  
Thailand  
Egypt 
2010 
2010 
2014 
2010 
48.5% 
82.7% 
70.59% 
94.4% 
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Formula:  
 
Ref. for the above formula: Lemeshow S, Hosmer DW, Klar J, Lwanga SK. Adequacy 
of Sample Size in Health Studies. John Wiley and Sons, 1990.  
6. Inclusion criteria  
6.1. Aseptic meningitis: Patients presenting to Department of Paediatrics or paediatric 
casualty with clinically suspected aseptic meningitis and CSF found to be negative for 
bacterial and fungal culture. 
6.2. Myocarditis: Patients admitted or seen in outpatient clinic and suspected to have 
myocarditis (with well characterized clinical signs of myocarditis) in Department of 
Cardiology, Department of Paediatrics, Paediatric ICU and Department of General 
Medicine. 
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6.3. Hand-foot and mouth disease: Patients presenting to the out-patient clinic of 
Dermatology and Paediatric casualty with well characterized lesions of hand-foot and 
mouth disease. 
6.4. Acute haemorrhagic conjunctivitis: Patients coming to outpatient clinic of 
Schell eye hospital with well characterized signs and symptoms of severe 
conjunctivitis with sub-conjunctival haemorrhage. 
7. Exclusion criteria 
1. Patients with clinically suspected aseptic meningitis whose CSF becomes positive 
for fungal or bacterial culture.  
2. Individuals who do not consent to the study.  
3. Patients in immunosuppressed state (patients diagnosed with HIV infection, patients 
on long term steroids, patients on chemotherapy)  
8. Study algorithm 
 
 
 
v 
 
 
 
Patients presenting 
to paediatric 
casualty or 
admitted in 
paediatric wards 
with symptoms 
and signs of 
aseptic meningitis 
Patients admitted in 
cardiology/general 
medicine/paediatrics 
with signs and 
symptoms of viral 
myocarditis 
Patients presenting to 
out-patient unit of 
Eye-hospital with 
symptoms and signs 
of acute 
haemorrhagic 
conjunctivitis 
Patients 
presenting to 
out-patient unit 
Dermatology/pae
diatrics with well 
characterized 
clinical features 
of hand foot and 
mouth disease 
Informed consent taken and patient proforma filled 
0.5 ml of CSF 
and 2 ml of 
blood was 
collected  
4 ml of blood 
was collected 
(pericardial fluid 
from 2 patients) 
Vesicular swab and 
2 ml of blood was 
collected (swab 
was placed in 
VTM immediately) 
Conjunctival swab 
and 2 ml of blood 
was collected (swab 
was placed in VTM 
immediately) 
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9. Collection and transport of samples 
9.1. Aseptic meningitis: An extra aliquot of 0.5ml of CSF sample was collected by the 
clinician from children brought to paediatric casualty or admitted in paediatric wards 
with clinically suspected aseptic meningitis. The samples were kept at 2-8
o
C. Once the 
principal investigator was informed, the samples were transported to the clinical 
virology laboratory at 2-8
o
C.          
All the samples were transported to the Virology lab at 2-8
o
C 
Serum was 
separated from all 
blood samples and 
was stored at -20
o
C 
CSF was stored as 
multiple aliquots at 
-80
o
C 
Separated plasma 
samples were 
stored at -80
o
C 
RNA extraction was done using  
RNA extraction protocol (Qiagen) 
After 1 week culture 
negative samples were 
recruited for the study 
IgM ELISA was 
performed on these 
serum samples 
Swabs (vesicular and 
conjunctival) were 
squeezed onto walls of 
VTM tube and centrifuged 
at 2000 rpm for 10 
minutes. Supernatant was 
stored as multiple aliquots 
at -80
o
C 
Screening was done with two real-time Pan-EV PCRs (EV1 &EV2) 
Sangers sequencing done for the    
positive samples 
Alignment using 
Bioedit  BLAST analysis  
A conventional PCR was standardised with samples positive for real time PCR 
Phylogenetic tree 
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9.2. Hand-foot and mouth disease: vesicular lesions were slightly punctured using a 
22 gauge needle and the vesicular fluid (only very small amount available) was 
collected onto a Nylon flocked swab and the swab was placed in tube containing viral 
transport medium and was transported to the clinical virology laboratory at 2-8
o
C.       
9.3. Myocarditis: 4ml of serum/plasma and/or pericardial fluid was collected from 
patients admitted or seen in outpatient clinic and suspected to have myocarditis in 
Department of Cardiology, Department of Paediatrics and Department of General 
Medicine, with well characterised symptoms and signs of myocarditis. The 
serum/plasma/pericardial fluid was transported to the clinical virology laboratory at 2-
8
o
C. 
9.4. Acute haemorrhagic conjunctivitis: Conjunctival swab sample was collected by 
the clinician using Nylon flocked swab from lower palpebral fissure of the patients 
coming to the outpatient department or casualty of Schell eye hospital with signs and 
symptoms of acute haemorrhagic conjunctivitis. After taking the sample the swab was 
placed in tube containing sterile viral transport medium (VTM) and was transported to 
the clinical virology laboratory at 2-8
o
C. 
10. Sample processing  
10.1. CSF: With all sterile precautions and appropriate personal protective equipment, 
collected CSF samples were aliquoted into 150 µl aliquots and were stored 
immediately at -80
o
C.  
10.2. Vesicular swab (HFMD), conjunctival swab (AHC): The tubes of viral 
transport medium(VTM) containing the swab were pulse vortexed for 2 minutes and 
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the swab was removed from VTM expressing all the fluid from the swab. Then the 
tubes were centrifuged at 2000 rpm for 10 minutes at 4
o
C and the supernatant was 
made into multiple aliquots of 150 µl and were stored immediately at -80
o
C. 
10.3. Plasma/serum: The tubes containing blood (with/without anticoagulant) were 
centrifuged at 2000 rpm for 10 minutes at 4
o
C to separate plasma/serum respectively. 
The separated plasma from the myocarditis patients were made into multiple aliquots 
of 150 µl and were stored immediately at -80
o
C. The separated plasma/serum from all 
patients in the study, for performing ELISA, was aliquoted and stored immediately at -
20
o
C. 
 
11. RNA extraction from samples 
11.1. Materials required: 
QIAamp Viral RNA mini kit (Qiagen, Germany), containing  
 Carrier RNA 
 Viral lysis buffer (AVL) 
 Wash buffers AW1 and AW2 
 Elution buffer (AVE) 
 Spin columns  
 Collection tubes 
Materials not provided with the kit:  
 Absolute alcohol 
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 Sterile Milli-Q water 
 1.5mL Micro centrifuge tubes 
 Micro-Pipettes (20-200µl, 100-1000µl) 
 Disposable filter plugged pipette tips (200µl, 1000µl) 
 Provial rack 
 Discard jar 
 Centrifuge  
 Vortex mixer 
 Disposable latex gloves 
 Disposable PVA gloves 
 Biosafety cabinet (BSL 2B) 
 
11.2. Procedure  
11.2.A. Preparation of reagents for RNA extraction:  
1) Viral lysis buffer (AVL): 310 μL of buffer AVE (elution buffer) was added to the 
carrier RNA tube. The tube was vortexed and spun momentarily. The entire contents 
of this tube (310µL) were transferred into the viral lysis buffer containing bottle and 
was mixed well. The AVL was stored at +4
0
C. 
2) Buffers AW1 and AW2: wash buffers were provided by the kit as a concentrate and 
appropriate amounts (mentioned in the kit) of ethanol (96-100%) were added to them 
before using. Wash buffers were stored at room temperature. 
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3) Buffer AVE (elution buffer) which was provided by the kit was ready-to-use and 
was stored at room temperature 
4) The appropriate volume of the reagents required was aliquoted into 15 ml Tarson 
tubes.  
11.2.B. Extraction of enterovirus RNA  
RNA extraction was performed as per manufacturer’s instructions. 
i) The appropriate centrifuge tubes containing processed and aliquoted samples were 
thawed by holding them at +4
0
C for 30 minutes. 
ii) 560 μL each of the prepared AVL was added to a 1.5 mL microcentrifuge tubes 
labelled appropriately. 140 μL of the vortexed samples were added to the appropriate 
microcentrifuge tubes. 
iii) The microcentrifuge tubes were pulse vortexed for 15 seconds and spun briefly at 
8000 rpm. The tubes were incubated at room temperature (22 to 25 ºC) for 10 minutes. 
iv) After the incubation, 560 μL each of absolute alcohol (96 - 100%) were added to 
the microcentrifuge tubes and pulse vortexed for 15 seconds and spun briefly at 8000 
rpm. 
v) 630 μL each of the mixture was transferred into the correspondingly labelled spin 
columns. The spin column-collection tube assembly was spun at 8,000 rpm for 1 
minute and then the collection tubes were discarded. 
vi) The spin columns were assembled with fresh collection tubes and the remaining 
630 μL each of the mixture was added to the spin columns. The spin column-collection 
50 
 
tube assembly was spun at 8,000 rpm for 1 minute and then the collection tubes were 
discarded. 
Vii) The spin columns were assembled with fresh collection tubes and 500 μL each of 
buffer AW1 was added to the spin columns. The spin column-collection tube assembly 
was spun at 8,000 rpm for 1 minute and then the collection tubes were discarded. 
viii) The spin columns were assembled with fresh collection tubes and 500 μL each of 
buffer AW2 was added to the spin columns. The spin column-collection tube assembly 
was spun at 14,000 rpm for 3 minutes and then the collection tubes were discarded.  
ix) The spin columns were assembled with fresh micro centrifuge tubes which are 
appropriately labelled and 60 μL each of buffer AVE (elution buffer) was added to the 
spin columns.  
x) This assembly was incubated at room temperature for 1 minute and then spun at 
8,000 rpm for 1 minute.  
xi) After this the spin columns were discarded and the microcentrifuge tubes 
containing the extract were stored temporarily in a chill tray at 4
0
C and used 
subsequently for PCR. 
xii) After loading the PCR the remaining RNA extracts were aliquoted into single use 
aliquots and were stored at -80
0
C. 
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12. Amplification of enterovirus (5’ UTR region) using Real time PCR I& II 
(EV1&EV2) 
 12.1. Materials required: 
1) ABI 7500Fast Real time PCR system with software 
2) AgPath ID One step RT-PCR kit, which includes 
 Master mix buffer 
 RT enzyme 
 Water (PCR grade supplied with the kit) 
3) Cooling block (96 well) 
4) ABI thermal cycling plate (96 well) 
12.2. Real Time PCR (EV I & EV II) 
12.2.A. Mastermix preparation – done in the clean room 
1) All the reagents needed for the preparation of master mix (stored in -20
0
C reagent 
freezer) were thawed, pulse vortexed and spun down briefly before use. 
2) Specific mastermix was prepared separately for EV-I PCR and EV-2 PCR adding 
different sets of primers and probe and also for GAPDH which serves as the internal 
control. The sequence of the primer for both the PCR‘s and GAPDH are given in the 
table below. 
Table 5: Primers and probes used for the amplification of 5’ UTR region of 
enteroviruses 
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Primers and Probe 
                                   
                                Sequence   
Working 
concentration 
 
   EV I Forward 
 
5' CAT GGT GYG AAG AGT CTA TTG AGC T 3'  
 
  
20 µM 
 
EV I Reverse 
 
5' GGA CAC CCA AAG TAG TCG GTT C 3'  
 
 
 20 µM 
 
EV I Probe 
 
5' Joe-CGG CCC CTG AAT GCG GCT AAT C-
BHQ2 3‘  
 
 
 10 µM 
 
EV II Forward 
 
  5‘ GGC CCC TGA ATG CGG CTA ATC C 3‘ 
 
 20 µM 
 
EV II Reverse 
  
  5‘ GCG ATT GTC ACC ATW AGC AGY CA 3‘ 
 
 20 µM 
 
EV II Probe 
 
  5‘ Fam-CCG ACT ACT TTG GGW GTC CGT NFQ-
MGB 3‘ 
 
 10 µM 
 
GAPDH 
Forward 
  
  5‘ GAA GGT GAA GGT CGG AGT 3‘ 
 
 20 µM 
 
GAPDH Reverse 
 
  5‘ GAA GAT GGT GAT GGG ATT TC 3‘ 
 
 20 µM 
 
GAPDH Probe 
 
  5‘Joe-CAAGCTTCCCGTTCTCAGCC-BHQ2 3‘ 
 
 10 µM 
 
3) Master Mix was prepared by addition of the following reagents. 
Table 6: Preparation of mastermix for real-time PCR 
                    
                   Reagents  
 
Volume for a single reaction (in µL) 
 
  Ag Path Master mix buffer 
  
                  12.5 
 
      Forward primer  
      (EV-I/EV-II/GAPDH) 
 
                   0.5 
      Reverse primer  
      (EV-I/EV-II/GAPDH) 
                   0.5 
         
 
      Probe(EV-I/EV-II/GAPDH) 
 
                   0.5 
 
      RT enzyme  
  
                   1 
   
      Nuclease free water 
 
                   5 
    
                    Total  
 
                  20 
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12.2.B. Loading of PCR plate: 
It is done by placing the PCR plate on the cooling block. 
1) 20 µL each of the appropriate master mix prepared was added to appropriate wells 
of the ABI thermal cycling plate as per the PCR template addition protocol. 
2) 5 µL each of the RNA extracts from the samples were added to the appropriate 
wells according to the PCR template. 5 µL of water was added as a negative control 
after every three consecutive samples. 5 µL of RNA extract from an in-house known 
positive sample (cell culture supernatant) also was used in each reaction with each 
target as a positive control.  
3) The plate was sealed with optical plate sealer and an even film was ensured over the 
plate 
4) The plate was loaded into the ABI 7500 Fast real time PCR system and the program 
was started after setting the cycling conditions given below. 
Table 7: Cycling conditions used for the real time PCR: 
 
          Feature  
 
        Temperature(°C) 
  
              Time  
 
          Hold 1 
 
                 48                
 
          10 min 
 
          Hold 2 
 
                 95 
 
          10 min 
  
          Cycling  
 
                 95 
 
          15 sec 
 
                 57 
 
          30 sec 
 
 
45 cycles  
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13. Quantification of the extract 
The extract quantification was performed by using spectrophotometer, Gen5 (Biotek). 
 
14. Conventional PCR amplifying VP1-2C region 
The samples which were amplified in any one of the two real time PCRs were 
amplified using a conventional PCR amplifying the VP1-2C region of the enterovirus 
genome. Before doing the conventional PCR the extracted RNA was converted into 
complementary DNA (cDNA).  
 14.1. cDNA conversion 
cDNA conversion was done by using M-MLV RT (Moloney Murine Leukemia Virus 
Reverse Transcriptase) enzyme. M-MLV RT is a recombinant polymerase which 
synthesizes a complementary DNA strand from the single-stranded RNA.  
14.1.A. Materials required:  
Materials provided with the kit: M-MLV cDNA synthesis kit 
 M-MLV RT (200 U/ µL) 
 5X First Strand Buffer [250 mM Tris-HCl (pH 8.3), 375 mM KCl, 15 
mM Magnesium Chloride] 
 100 mM DTT 
Materials not provided with the kit 
 dNTP mix 10mM 
 RNaseOUT™ Recombinant Ribonuclease Inhibitor (40 units/μL) 
 Nuclease free water 
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 Primers (EUC2a, EUC2b – 10pmol each) 
14.1.B. Mastermix preparation 
             The following set of degenerate primers were used for the cDNA 
conversion(87).  
Table 8: Primers used for cDNA conversion 
                       Primer                                     Sequence  
 
        EUC2a 
 
5‘ GGT TCA ATA CGG CAT TTG GA 3‘  
 
 
        EUC2b 
 
5‘ GGT TCA ATA CGG TGT TTG CT 3‘  
 
 
Table 9: Mastermix preparation for cDNA conversion 
               Reagents  Volume for a single reaction (in µL) 
           MMLV buffer                              6 
           Primers (EUC2a, EUC2b)                              1 
           dNTP                              2 
           DTT                              2.2 
           RT enzyme                               1 
           RNase out                              2.3 
           Nuclease free water                             14.5 
           Total                             29 µL 
 
The mastermix was aliquoted into PCR tubes. 1 µL (50 ng) of each of the RNA 
extracts of the samples, which were amplified by the real time PCR, were added to the 
56 
 
corresponding tubes. The cDNA conversion was carried out in thermal cycler, 
GeneAmp (Applied Biosystems, Foster City, California, USA). 
Table 10: Cycling conditions of cDNA conversion 
                     
           Temperature  
 
                        Time            
                 
                  42 °C 
 
                      60 minutes 
 
                  94 °C 
 
                      5 minutes  
                      
 
14.2. Conventional PCR 
A conventional PCR was used to amplify the VP1-2C region of enteroviruses (in the 
samples which are amplified by the real-time PCR) using a set of four degenerate 
primers (87).  
 
Table 11: Primers used for the conventional PCR 
        Primer                             Sequence  
 
        EUC2 
 
5‘ TTT GCA CTT GAA CTG TAT GTA 3‘  
 
 
        EUG3a 
 
5‘ TGG CAA ACT TCC WCC AAC CC 3‘  
 
 
        EUG3b 
 
5‘ TGG CAA ACA TCT TCM AAT CC 3‘  
 
 
        EUG3c 
 
5‘ TGG CAG ACT TCA ACH AAC CC 3‘  
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14.2.A. Preparation of mastermix: 
The preparation of mastermix for the conventional PCR was done in the clean room by 
addition of reagents according to the table given below.  
Table 12: Mastermix preparation for conventional PCR 
            Reagents  Volume for a single reaction (in µL) 
 Hot Start Master Mix                           25 
 Primers (EUC2, EUG3a, EUG3b, EUG3c)                          2 (10picomol each) 
 Nuclease free water                          23 
 cDNA                          2 
Total volume                          50 µL 
 
The mastermix was prepared and aliquoted as 48 µL into PCR tubes. To each tube 2 
µL of corresponding cDNA was added. The PCR was carried out in thermal cycler, 
GeneAmp (Applied Biosystems, Foster City, California, USA). 
Table13: Cycling conditions for the conventional PCR: 
Steps  Temperature  Duration  Number of Cycles  
Hold 1 95 10 minutes  
Hold 2 95 20 seconds  
         
 35 cycles  45 1 minute 
72 1 minute 
Hold 3 95 20 seconds  
          
Final cycle  45 1 minute 
72 10 minutes 
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14.3. Gel electrophoresis: 
The amplified products were run on an ethidium bromide-stained 2% agarose (Sigma 
Aldrich Inc., St Louis, MO, USA) gel to check for the specific base pair size amplicon 
(1452 bp). The agarose gel is visualized using the gel documentation system Geldoc 
2000 (BioRad, CA, USA) using the software Quantity One version 4.1.1 (BioRad, CA, 
USA).  
14.3.A. Materials required: 
(i) Gel casting tray & Comb to make sample slots 
(ii) Agarose – molecular grade  
(iii) 100 ml of 1X TAE buffer 
(iv) Ethidium bromide  
(v) Loading (Gelpilot) dye 
(vi) 1500 bp molecular ladder 
(vii) Electrophoresis tank 
(viii) Geldoc 2000 documentation system 
(ix) Calibrated pipettes (1-20 µl, 20-200 µl) 
(x) Corresponding pipette tips 
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14.3.B. Procedure: 
1) The agarose gel casting tray and the appropriate comb for sample slots were 
arranged. 
2) 2 g of agar was weighed and dissolved in 100 ml of 1X TAE buffer in a round 
bottomed glass flask and kept in a microwave and boiled. 
3) 40 µl of ethidium bromide solution was added to the liquid agarose after cooling 
and after mixing well, this mixture was poured into the agarose gel casting tray fitted 
with the comb. 
4) Agarose gel was left to set for 15-20 minutes. 
5) After the agarose gel was set, the comb was removed and agarose gel was placed in 
the electrophoresis tank. 
6) The electrophoresis tank was filled with 1X TAE buffer working solution (prepared 
by mixing 980 ml of MiliQ water and 20 ml of 50X TAE buffer). 
7) 5 µl of the 1500bp molecular ladder was added to the first well. 
8) 3 µl of the loading dye and 5 µl of the amplicon were mixed and transferred in the 
respective wells, along with positive and negative controls. 
9) Gel was run at 120 Volts for 40 minutes. 
10) After the electrophoresis was completed, gel was visualized using the gel 
documentation system (BioRad, California, USA). 
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11) The band size of the amplicon was compared with the known base pair size in the 
molecular ladder to confirm whether the expected target has been amplified. 
14.4. Modifications for unamplified samples in conventional PCR 
For the positive samples which were not amplified by the conventional PCR, cDNA 
conversion was repeated by increasing the input of RNA (up to 350 ng) followed by 
conventional PCR. If still not amplified, further increased input of cDNA (up to 5 µl) 
was used in the conventional PCR. 
15. Pre-sequencing clean-up 
The amplified products in the amplification tubes were purified with Millipore 
(Billerica, MA, USA) plates by vacuum drying. The pre-sequencing clean up steps 
were as follows: 
1) The amplified product from the PCR was made up to a final volume of 100 µl using 
sterile MilliQ water. 
2) The diluted contents were transferred to the corresponding wells of a Millipore plate 
and connected to a Millipore vacuum manifold. 
3) Negative pressure was applied for approximately 15 minutes or until the well is 
completely dried. 
4) 100 µl of sterile MilliQ water was added and previous step was repeated.  
5) On complete drying of wells, 20 µl of sterile MilliQ water was added to wells and 
the plate was kept on mechanical shaker for 2 minutes at 7000 rpm. 
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6) The purified DNA was aspirated from the wells of the Millipore plate and was 
transferred to pre-labelled PCR tubes.  
 
16. Sequencing PCR 
The sequencing was performed by using 3 forward primers (EUG3a, EUG3b and 
EUG3c) and one reverse (EUC2) primer as shown in the table below. These primers 
were freshly reconstituted for each use to a final concentration of 1 picomole/ µl. 
Table 14: Primers used for sequencing 
                        Primer  Sequence  
                       EUC2 5‘ TTT GCA CTT GAA CTG TAT GTA 3‘  
                       EUG3a 5‘ TGG CAA ACT TCC WCC AAC CC 3‘  
 
                       EUG3b 5‘ TGG CAA ACA TCT TCM AAT CC 3‘  
 
                       EUG3c 5‘ TGG CAG ACT TCA ACH AAC CC 3‘ 
  
 
 
The other reagents used for sequencing are Ready Reaction buffer (ABI PRISM Big 
Dye terminator cycle sequencing reagent, Applied Biosystems, USA) and Ready 
Reaction mix (ABI PRISM Big Dye terminator cycle sequencing reagent, Applied 
Biosystems, USA). The ingredients of mastermix and the cycling conditions for 
sequencing are given in the tables below.  
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Table 15: Mastermix preparation for sequencing PCR 
Reagents  Volume for single reaction (µl) 
5x sequencing buffer                         2 
Ready reaction mix                         1 
Freshly reconstituted primer (1pmol/ µl)                         3.2 
Milli Q water 
 
                        2.8 
Purified PCR product                         1 
Total volume                          10 µl  
 
Table 16: Cycling conditions for sequencing PCR 
               Temperature                 Time  
                       96°C             15 minutes 
                       50°C             20 seconds 
                      60°C             4 minutes 
                      15°C            30 minutes  
 
The sequencing PCR was carried out in thermal cycler, GeneAmp (Applied 
Biosystems, Foster City, California, USA). 
17. Post-sequencing clean-up 
The sequenced samples were then subjected to post-sequencing clean up using a 
Millipore vacuum system. The steps of purification were as follows: 
25 cycles 
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1) The sequenced product was made up to 40 µl using injection solution. 
2) The diluted product was transferred to the Millipore microtiter plate and attached to 
a Millipore vacuum manifold. 
3) Vacuum pressure was applied for approximately 10 minutes or until the well dried. 
4) On drying of the wells 40 µl of injection solution was added and step 3 was 
repeated.  
5) On complete drying of the wells, 30 µl of injection solution was added and mixed 
for 2 minutes on a mechanical shaker and the products were transferred to PCR tubes 
for analysis. 
18. Sequence analysis   
The output of sequencing was in the form of an electropherogram. Pairwise alignment 
of the nucleotide sequences obtained by forward and reverse primers was done by 
using BioEdit sequence alignment editor version 7.09.0. The analysed sequences were 
compared to the reference sequences in GenBank using NCBI BLAST.  
19. Phylogenetic analysis  
Phylogenetic analysis was conducted using MEGA (Molecular Evolutionary Genetics 
Analysis) version 6 (Tamura, Stecher, Peterson, Filipski and Kumar 2013). 
20. Inter assay – intra assay variability analysis 
20.1. Real-time Pan-Enterovirus PCR-1 & 2 targeting 5’-UTR region 
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Three known positive samples were used in triplicates in two different real-time PCR 
assays to look for inter and intra assay variability. The intra-assay and inter-assay co-
efficient of variation was determined for both the real-time PCRs. 
20.2. Conventional PCR targeting VP1-2C region 
Inter and intra assay variability was analysed by performing two conventional PCRs 
using a known positive sample in triplicate.  
21. Human Coxsackie Virus IgM ELISA  
21.1. Principle 
This assay is based on sandwich enzyme-linked immunosorbent assay (ELISA). 
Serum samples containing Coxsackie Virus IgM (Cox V-IgM) antibodies react with 
anti- Coxsackie Virus IgM antibodies which are pre-coated in the wells. After 
incubation, biotin labelled antibodies against Coxsackie Virus IgM (Cox V-IgM) is 
added into the wells. It binds to the complex and forms a sandwich. Then streptavidin-
HRP is added to the wells. After incubation unbound reagents are washed away. TMB 
substrate is added to the wells. The amount of hydrolysed substrate is read using a 
spectrophotometer. This is directly proportional to the concentration of Coxsackie 
Virus IgM (Cox V-IgM) antibody in the sample. 
  
21.2. Materials required 
Cox V-IgM ELISA kit (KRISHGEN BioSystems) Version 2.0 
Materials provided with the kit: 
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1. Microtitre Coated Plate (96 wells)   
2. Cox V-IgM Ab Biotin Conjugate    
3. Standard, 40pg/ml 
4. HRP Conjugate  
5. Wash Buffer (30X)   
6. Standard Diluent   
7. Substrate A  
8. Substrate B 
9. Stop solution    
Materials not provided with the kit: 
1. Microplate Reader able to measure absorbance at 450 nm 
2. Adjustable pipettes to measure volumes ranging from 50μl to 1000μl 
3. Deionized (DI) water 
4. Wash bottle or automated microplate washer 
5. Semi-log graph paper or software for data analysis 
6. Tubes to prepare standard/sample dilutions 
7. Timer 
8. Absorbent paper 
21.3. Reagent preparation 
1. Before use, all reagents were brought to room temperature. 
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2. 1X Wash Solution was prepared by adding 10ml of 30X Wash Buffer in 290ml of 
DI water. 
21.4. Procedure 
1. All Standards and Samples were run in duplicates. 
2. The standards were prepared as per the table given below using the provided 
original standard and standard diluent. 
Table 17: Preparation of standards 
Standard number                     Dilution     Final concentration 
           5 120μl Original Standard (40pg/ml) + 
120μl Standard diluent 
         20pg/L 
           4 120μl Standard No.5 + 120μl Standard 
diluent 
           10pg/L 
           3 120μl Standard No.4 + 120μl Standard 
diluent 
           5pg/L 
           2 120μl Standard No.3 + 120μl Standard 
diluent 
           2.5pg/L 
           1 120μl Standard No.2 + 120μl Standard 
diluent 
          1.25pg/L 
 
3. 50μl of Standards and 40μl of Samples were added into the respective wells in 
duplicates. No sample was added to the blank well.  
4. 10μl of Ab Biotin Conjugate was added into each sample well. It was not added into 
the blank and standards wells. 
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5. 50μl of HRP Conjugate was added into each sample and standards well, not into the 
blank well.  
6. The plate was covered and incubated for 1 hour at 37°C in the incubator. 
7. The contents of the wells were aspirated and the plate was washed 4 times with 1X 
Wash Buffer and residual buffer was blotted by firmly tapping the plate upside down 
on an absorbent paper. 
8. 50μl of Substrate A and then 50μl of Substrate were added in each well including 
Blank well. 
9. The plate was incubated at 37°C for 10 minutes in dark. Positive wells turned blue 
in colour. 
10. 50μl of Stop Solution was added to all the wells. The wells turned blue to yellow.  
11. The absorbance was read at 450 nm within 15 minutes after adding stop solution 
blanking on the zero standards. 
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Figure 6: The ELISA plate showing the controls and standards (C1 – D1; 
standards in duplicate, E1&F1; zero standard, G1 – H12; patient samples) 
 
22. Statistical analysis 
Descriptive statistics were used, such as number and percentage for categorical 
variable and Mean and SD or median with inter quartile range (IQR) for all the 
continuous variables. However, Histogram was done for continuous variables to study 
the distribution. When the histogram suggested normal distribution, Analysis of 
variance (ANOVA) was applied, and if the distribution does not follows normal, 
Mann-Whitney U test was used to compare between groups. The Intra class 
correlation was used, to compare the two methods EV1 Ct and EV2 Ct and Bland 
Altman plot was presented with precision and percentage error was reported to assess 
the two methods.  P value at 5% level significance will be considered as statistical 
significance. The analysis was carried out using SPSS software 16.0 version.  
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                                                     RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total number of samples (n=81) were collected for molecular typing from a total of 79 
patients with hand foot and mouth disease (31), aseptic meningitis (26), myocarditis (20 
samples from 18 patients) and acute haemorrhagic conjunctivitis (4). These satisfied the 
inclusion/exclusion criteria and they were characterized based on age, gender, geographic 
distribution, location of sample collection and month and year of sample collection. 
 i) Standardization of a real-time RT-PCR (EV2), targeting the 5‘-UTR region of 
enteroviruses, was done. This PCR was used to detect enteroviruses from all the 81 
samples.   
ii) Another real-time RT-PCR (EV 1), targeting the 5‘-UTR region of enteroviruses, using 
a different set of primers and probe from EV 2, also was done on all the samples. 
iii) The intra and inter-assay variability was analysed and determined for both the real-
time PCRs. 
 i) Conventional PCR targeting VP1 – 2C region of enteroviruses for all the samples with 
CT value </= 30 in EV 1 real-time PCR was done. 
ii) Sequencing of samples positive in conventional PCR and phylogenetic tree 
construction was carried out. 
iii) Intra and inter-assay variability of conventional PCR was done and analysed. 
EV 1 positive = 31/81 (38.27%); EV 2 positive = 26/81 (32.10%) 
Conventional PCR positive = 12/25 (48%); sequencing results  9/12 = 
Coxsackievirus A6, 3/12 = Coxsackievirus A16 
i) A total of 42 samples were collected for serology from consented patients.  
ii) Human coxsackievirus IgM ELISA done with all the serum samples. 
iii) 30 age stratified control serum samples from healthy individuals were retrieved from 
the archived samples and the same ELISA was performed to determine cut off value. 
 
ELISA = mean OD values of HFMD and myocarditis samples are 
significantly higher than that of control samples  
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1. Baseline characteristics 
1.1. Samples collected for the study  
A total of 81 samples were collected from 79 patients satisfying the inclusion and 
exclusion criteria for the molecular typing of enteroviruses. Out of the 81 samples 
collected, 31 vesicular fluid samples (38.27%), 26 cerebrospinal fluid samples 
(32.10%), 18 plasma samples (22.22%) and 4 conjunctival swab samples (4.94%) 
were collected from patients with hand foot and mouth disease, aseptic meningitis, 
myocarditis and acute haemorrhagic conjunctivitis respectively. Two pericardial fluid 
samples (2.47%) also were collected from two of the myocarditis patients. 
 
Figure 7: Distribution of the types of study samples for PCR.  
 
For performing the ELISA to estimate the sero-prevalence of enteroviruses, 42 
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hand foot and mouth disease patients, 2 samples (4.8%) were from aseptic meningitis 
patients, 18 samples (42.86%) were from myocarditis patients and 4 samples (9.50%) 
were from acute haemorrhagic conjunctivitis patients. 
 
Figure 8: Distribution of the samples for serology among the study populations.  
 
1.2. Age wise distribution  
Among the patients recruited for this study 53 (67%) patients belong to the age group 
5 years and below, 12 (15%) were of 6 to 15 years and the rest of the 14 (18%) were 
adults.  
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Figure 9: Age wise distribution of all the patients included in the study. 
 
Among the HFMD patients 23 (74.20%) were in the 0 – 5 years group, 3 (9.68%) 
were in 6-15 years group and 5 (16.13%) were adults (>15 years). In the aseptic 
meningitis group 20 (76.92%) patients were 5 years and below, and 6 (23.08%) 
belonged to 6 to 15 years of age. Out of 18 myocarditis patients 10 (55.56%) were 5 
years and below, 3 (16.67%) were in 6 to 10 years age group and 5 (27.78%) were 
adults. All the acute haemorrhagic conjunctivitis patients were adults.  
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Figure 10: Age wise distribution of patients in different study groups.  
1.3. Gender wise distribution 
Out of 79 patients included in the study 49 (62.02%) were males and 30 (37.97%) 
were females. 
 
Figure 11: Gender wise distribution of all the patients included in the study. 
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1.4. Geographic distribution of the patients  
 
Among 79 patients included in the study 50 (63.29%) were from Vellore district, 8 
(10.13%) were from other districts of Tamilnadu, 2 (2.53%) were from Bangladesh 
and the remaining 19 (24.05%) patients were from other states of India. The 
geographic distribution of the patients in each disease group is shown in Table 18.  
Table 18: Geographic distribution of patients in each disease group. 
Geographic 
region 
HFMD Aseptic 
meningitis 
Myocarditis  Acute 
haemorrhagic 
conjunctivitis 
 
Vellore  
 
23 
 
18 
 
6 
 
3 
Other districts 
of Tamilnadu 
 
2 
 
2 
 
4 
 
Nil  
 
Chittoor  
 
2 
 
4 
 
3 
 
Nil  
 
Kerala  
 
Nil  
 
Nil  
 
3 
 
1  
 
Karnataka  
 
1 
 
Nil  
 
Nil  
 
Nil  
 
West Bengal  
 
2 
 
1 
 
Nil  
 
Nil  
 
Bangladesh  
 
1 
 
Nil  
 
1 
 
Nil  
 
Jharkhand  
 
Nil  
 
1 
 
Nil  
 
Nil  
 
Assam  
 
Nil  
 
Nil  
 
1 
 
Nil  
 
Total  
 
31 
 
26 
 
18 
 
4 
 
1.5. Location of sample collection  
Majority of the samples (28/31, 90.32%) from HFMD patients were collected from the 
Dermatology outpatient unit, 2 (6.45%) of them were from the paediatric ward and 
one (3.22%) from the haematology outpatient unit which was referred to dermatology.  
75 
 
The samples from aseptic meningitis patients were collected mainly from paediatric 
casualty (21/26, 80.77%) and the remaining samples (5/26, 19.23%) from paediatric 
ward.  
Most of the myocarditis samples were collected from Paediatric ICU or HDU, and 
others were collected from Bone marrow transplant unit (BMTU), Adult ICU (AICU), 
paediatric ward and medical ward. 
 
Figure 12: Distribution of the myocarditis patients according to the location of 
sample collection 
All the four acute haemorrhagic conjunctivitis samples were collected from the 
outpatient unit of the ophthalmology department.  
Distribution of HFMD cases during study period 
The HFMD cases showed a clustering during a period from October 2017 – December 
2017, constituting 26 cases out of 31 (83.87%) cases of HFMD included in the study.  
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Figure 13: Line diagram showing the distribution of HFMD cases throughout the 
study period. 
Clinical features 
Hand foot and mouth disease  
Among the 31 HFMD patients included in the study, 22 (70.97%) had fever as a 
prodromal symptom. The papulo-vesicular lesions characteristic of HFMD was 
present on different sites in different patients as depicted in Figure 14.  
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Figure 14: Distribution of the papulo-vesicular rashes on different sites of the 
body. 
                                   
                    Figure 15: Papular lesions of HFMD on the palms of a study patient           
               Image coutesy: Dr. Dincy Peter, Professor, Department of Dermatology, CMC vellore  
 
Real-time PCRs targeting the 5’-UTR region of enteroviruses 
In the real-time PCR-1 (EV1), 32 samples (HFMD=27, aseptic meningitis=4, AHC=1) 
were positive (Ct value of </= 37 is taken as positive), whereas in the real-time PCR-2 
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(EV2) with the same target, but with a different set of primers and probe, only 26 
samples (only HFMD) were positive and Ct values were higher than that of EV1. 
 
Figure 16: Number of samples positive in real-time PCRs 1 and 2 (EV1 and EV2) 
 
Figure 17: Real-time PCR 2 (EV2) amplification plot showing the curves of the 
positive control and a positive study sample (HFMD 10). 
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Comparison of two real-time PCRs amplifying the 5’-UTR region of enterovirus 
genome 
The results of the real-time PCRs in terms of positivity (Ct value </= 37) and 
negativity (Ct value > 37) were compared and showed a good agreement of 84% 
(κ=0.814, p value < 0.001).  
The Ct values were available in both the real-time PCRs only for 26 samples and all of 
them were samples from HFMD patients. The Ct values of these 26 samples were 
compared using intra-class correlation and the correlation co-efficient was found to be 
0.934 (95% confidence interval: 0.858 – 0.970) which is significant.  
 
Figure 18: Scatter plot showing correlation between the Ct (cycles threshold) 
values of real-time PCRs EV1 (X-axis) and EV2 (Y-axis) 
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Bland-Altman plot analysing Ct values of the 26 samples with Ct values available for 
both of the real-time PCRs, EV1 and EV2 showed a high agreement, as depicted in 
Figure 19. 
 
Figure 19: Bland-Altman plot showing correlation between the Ct values of the 
real-time PCRs EV1 and EV2. 
Intra and inter-assay variability testing 
The intra and inter-assay variability was tested by running three positive samples in 
triplicates, twice using both the real-time PCRs (EV1 and EV2). The intra and inter-
assay co-efficient of variation was determined for all three samples in both the PCRs 
which are shown in Table 19. 
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Table 19: Intra and inter-assay co-efficient of variation. 
 
Samples  
EV1- Run1 
Intra-assay 
CV% 
EV1- Run2 
Intra-assay 
CV% 
Run1-Run2 
Inter-assay 
CV% 
EV2 – Run1 
Intra-assay 
CV% 
EV2 – Run2 
Intra-assay 
CV% 
Run1-Run2 
Inter-assay 
CV% 
Sample 1 0.098 0.106 0.554 0.197 0.233 4.67 
Sample 2 0.145 0.144 0.433 0.015 0.159 5.20 
Sample 3 0.165 0.145 1.146 0.114 0.11 3.73 
 
 
Amplification of VP1-2C region of enterovirus genome 
From the 32 samples which are amplified in the real-time PCR1 (EV1), the samples 
which are having a CT value of </= 30 (25 samples) were selected for the 
amplification of VP1-2C region by a conventional PCR for sequencing and molecular 
typing. RNA quantification was done for all the 25 samples and 50ng of the extract 
obtained by using Qiagen RNA extraction kit was used for cDNA conversion which 
was followed by amplification and sequencing. Out of this 25, only 7 samples got 
amplified by using an input of 50 ng of extract. For the unamplified samples the input 
of the extract was increased to a maximum of about 350 ng and 5 more samples were 
amplified. The amplified products were run on an ethidium bromide stained 2% 
agarose gel to look for specific base pair size amplicons (1452 bp). A representative 
picture of gel documentation is shown in Figure 20. 
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Figure 20: A representative gel documentation picture of the amplified product 
of the PCR targeting the VP1-2C region of enteroviruses (Lane 1: Molecular 
ladder; Lane 3: Positive control; Lane 4: Positive sample; Lane 5: Negative 
sample). 
A sample which was amplified in the conventional PCR was used for testing the intra 
and inter-assay variability of the PCR. The sample was used in triplicate with water in 
between in both the assays. It was amplified and showed a band in the gel picture in 
all the triplicates. A representative image of the gel picture of intra assay variability 
testing is shown in Figure 21. 
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Figure 21: A representative gel picture (Run 2) showing the intra-assay and 
inter-assay variability testing of the conventional PCR using a positive sample 
(LANE 1: molecular ladder, LANE 3,5,7: Positive sample, LANE 4,6: water)  
Sequencing  
All the samples amplified by the conventional PCR targeting VP1-2C region were 
sequenced by the conventional Sanger‘s sequencing method and electropherograms 
were obtained. A representative electropherogram of a sample using one of the 
primers is shown in Figure 22. 
 
Figure 22: Representative electropherogram of the sequences of one of the 
samples. 
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The sequences obtained by the forward (EUG3c or EUG3a) and reverse (EUC2) 
primers were compared with the sequences available in GenBank database using the 
program NCBI BLAST (Basic Local Alignment Search Tool) version 2.8.0 and the 
molecular types were determined. 
Among the 12 samples sequenced 9 (75%) were coxsackievirus A6 and 3 (25%) were 
coxsackievirus A16.  
 
Figure 23: The molecular types obtained by Sanger’s sequencing  
Pairwise alignment of the nucleotide sequences obtained by forward and reverse 
primers was done by using BioEdit sequence alignment editor version 7.09.0. 
Alignments were corrected manually to get maximum sequence identity with the 
reference sequences in the GenBank. A representative image of which is shown in 
Figure 24. 
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Figure 24: Representative image of pairwise alignment of forward and reverse 
sequences using BioEdit sequence alignment editor.             
 
Phylogenetic analysis: 
 Phylogenetic analysis of the sequences obtained was conducted using MEGA 
(Molecular Evolutionary Genetics Analysis) version 6 (Tamura, Stecher, Peterson, 
Filipski and Kumar 2013). The sequences of the study samples were compared with 
the reference strains available in GenBank. 
86 
 
 
Figure 25: Phylogenetic tree showing the relationship of the study isolates 
(marked with green circles) with the reference sequences.  
  
 
 
HEV A 
HEV B 
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Human Coxsackievirus IgM ELISA 
Human coxsackievirus IgM ELISA was performed with serum samples from 42 
patients belonging to all the disease groups as shown in Figure, and 30 age stratified 
healthy controls. Five standard concentrations provided by the kit also were used for 
the assay. A standard curve was created using the concentrations  of the standards and 
the unknown concentrations of the samples (both cases and controls) were 
interpolated using the standard concentrations.  
Median concentration of the Human coxsackievirus IgM antibody in the serum 
samples of the  controls was found to be 2.89 pg/ml (interquartile range: 1.79 – 23.29 
pg/ml), of serum samples from HFMD patients was 12.68 pg/ml (interquartile range: 
2.35 – 35.59 pg/ml) and that of myocarditis samples was 6.93 pg/ml (interquartile 
range: 2.57 – 25.64 pg/ml). The median concentration of the IgM antibodies in the 
HFMD patients is found to be significantly higher than that of the controls (p=0.027). 
But, the median concentration of the IgM antibodies in the myocarditis patients  do 
not show a significant difference from that of the controls (p=0.194). 
Median OD value of the ELISA for the controls was 0.14 (interquartile range: 0.08 – 
1.31), for the HFMD patients was 1.08 (interquartile range: 0.19 – 3.06) and for the 
myocarditis patients was 0.58 (interquartile range: 0.21 – 2.2). The median of the OD 
values of both the HFMD patients (p=0.002) and the myocarditis patients (p=0.013) 
were found to be significantly higher than that of the controls. 
The variation in the concentrations of the Human coxsackievirus IgM antibodies in the 
controls, HFMD patients and the myocarditis patients is represented as follows. 
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Figure 26: Box and whisker plot showing the comparison between the 
concentrations of the Human coxsackievirus IgM antibodies in the controls, 
HFMD patients and myocarditis patients. 
The variation in the OD values obtained from the ELISA at 450nm, of the controls, 
HFMD patients and the myocarditis patients is represented as follows. 
 
-10
-5
0
5
10
15
20
25
30
35
40
45
Control HFMD Myocarditis
C
o
n
ce
n
tr
a
ti
o
n
 (
p
g
/m
l)
 
Groups of patients and controls 
Box plot of the concentrations of Human coxsackievirus IgM antibody 
of controls and cases  
-1
0
1
2
3
4
5
Control HFMD MyocarditisO
D
 v
al
u
e
s 
o
f 
th
e
 E
LI
SA
 a
t 
4
5
0
n
m
 
 
Groups of patients and controls 
Box plot of the OD values of the Human coxsackiecirus IgM ELISA  
89 
 
Figure 27: Box and whisker plot showing the comparison between the OD values, 
obtained from the Human coxsackievirus IgM ELISA, of the controls, HFMD 
patients and myocarditis patients. 
Median concentration of the Human coxsackievirus IgM antibody in the serum 
samples of HFMD patients with a positive real-time enterovirus PCR result was found 
to be 28.72. This was compared with the median concentration of the controls, which 
is 2.89. The median concentration of IgM antibody in PCR positive HFMD patients 
was significantly higher than that of the controls (p=0.0036).   
The variation in the concentrations of the Human coxsackievirus IgM antibodies in the 
controls and the HFMD patients with positive PCR results is represented as follows. 
 
Figure 28: Box and whisker plot showing the comparison between the 
concentrations of the Human coxsackievirus IgM antibodies in the controls and 
HFMD patients with positive result for enterovirus PCR. 
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                                                              DISCUSSION 
Non-polio enteroviruses are responsible for a wide spectrum of clinical manifestations 
throughout the world, leading to significant morbidity and mortality. Enteroviruses 
affect all age groups, particularly young children (106). The infections caused by the 
non-polio enteroviruses are more common during summer and fall months of the year 
causing apparent and inapparent infections. Even though most of the infections caused 
by them are asymptomatic, they can cause severe infections like aseptic meningitis, 
encephalitis, myocarditis etc, which may lead to permanent sequelae and even death 
(7). The transmission of enteroviral infections is mainly through faeco-oral route and 
rarely by other routes like direct contact, fomites, respiratory route etc, depending on 
the type of infection. There are more than 100 serotypes of non-polio enteroviruses 
causing infections in humans (4).  
In this study, we have collected samples from patients with hand foot and mouth 
disease, aseptic meningitis, myocarditis and acute haemorrhagic conjunctivitis during 
a period of 16 months from April 2017 to July 2018.    
Among the HFMD patients included in this study, 74.20% were in 0 – 5 years group, 
which is the commonest age in which HFMD affects the children. This is in 
accordance with the study done by Bendig et al in 1996 in England and Wales where 
children of 1-4 years were most affected. The causative agent was EV 71 (107). Xia et 
al in 2016 in East China had also reported an outbreak of HFMD where majority of 
the affected population was of 1-3 years (108). In Singapore during 2001-2007, an 
epidemiological study undertaken by Ang et al found that 0-4 years is the age group 
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which is affected most commonly by HFMD (109). However, in an outbreak of 
HFMD in Odisha, India, in 2013, children of age 5-14 years were most affected (110).  
In the study period the HFMD cases showed a clustering (83.87%) during the winter 
(October – December) which is in contrast to the usual pattern of the disease which is 
during post-summer and fall seasons, as seen in various outbreaks. Xia et al studied 
the epidemiology of HFMD in East China during 2011 – 2014, which showed a high 
peak incidence from May to July (108). Wang et al describes a clear relationship 
between the occurrence of HFMD cases and the monthly precipitation pattern of that 
region (111).  
Until recently, the gold standard for the diagnosis of enteroviral infections was 
considered to be viral culture and isolation. However, later various studies have shown 
conclusively that the detection of a part of the genome by PCR has almost double 
sensitivity than the viral culture. The commonest region of the genome used as a 
target is the 5‘-UTR, which is the most conserved region among the enteroviruses. 
This has an increased sensitivity for the detection of enteroviruses in clinical 
specimens. This region has been used for the detection of enteroviruses in clinical 
samples by  Gomara et al in 2006 (112), Hong et al in 2010 (113), Tryfonos et al in 
2011(114) and by various other studies also.  
 In this study two real-time RT-PCRs targeting 5‘-UTR were used to amplify the 
enterovirus genome and they were compared. The positivity by both the PCRs showed 
a good agreement of 84% (κ=0.814, p value < 0.001). However, the Ct values of real-
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time PCR-1 (EV1) were significantly lower than those of real-time PCR-2 (EV2), 
which showed that the former one is the more sensitive PCR than the latter.  
Among the vesicular swab samples collected from HFMD patients, 25 were positive 
by both the PCRs, which showed that the samples had a significant viral load to be 
detected by the PCR. HFMD has been diagnosed by various other studies from the 
vesicular fluid (115) and also from other samples like throat swab, stool sample (108), 
rectal swab (116) and even from urine sample (117). This shows that the virus is shed 
in different body fluids.  
For all the myocarditis patients included in the study, the plasma samples were 
negative in both the real-time PCRs. The initial viremia in enterovirus myocarditis is 
transient. In the initial phase there is direct destruction of cardiomyocytes due to virus-
mediated lysis. However, this phase usually goes unnoticed since the innate immune 
response usually prevents the initial damage. Only in the secondary phase when there 
is also an autoimmune destruction of the cardiomyocytes, the disease manifests and by 
this time the viremia resolves (118). Hence it is difficult to detect the virus directly 
from blood or plasma by molecular methods. The negativity of PCR for all the plasma 
samples may be attributed to these reasons. The ideal sample for the detection of 
enterovirus in myocarditis is considered to be endomyocardial biopsy tissue (119), 
which was not feasible in our study.  
For the molecular characterization and typing, different regions of the enteroviral 
genome have been evaluated by various studies. In 1998, Oberste et al used two 
primers in the conserved regions of 5‘-UTR and VP2, to amplify and sequence a 
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region covering VP4 and the aminoterminal part of VP2; however, in this region there 
was no absolute correlation between the serotype and genotype (90). The P3 region 
also has not shown any correlation between the serotype and genotype according to 
Casas et al, 2001 (120). Conversely, the VP1 region shows a very good correlation 
with the serotypes. Therefore it is used for the molecular typing of enteroviruses by 
various methods. Oberste et al., 1999 (86), Caro et al., 2001 (87) and Norder et al., 
2001 (121) used this method for the typing of enteroviruses. In the mature 
picornavirus virion, VP1 is the major surface accessible protein and it even 
contributes to the three important neutralization sites on the surface of poliovirus 
(122). We have used a set of degenerate primers, which is used by Caro et al., 
amplifying the VP1-2C region for the molecular typing of enteroviruses (87). 
However, most of the RT-PCR methods previously described for the molecular 
characterization and typing of enteroviruses require propagation of the virus in cell 
culture because these assays are not sensitive enough to yield a sufficient amount of 
the amplicon to be detected by gel electrophoresis, from clinical specimens with low 
viral loads. Caro et al., also used cell culture to propagate the virus from the clinical 
sample followed by PCR and sequencing from the culture extract (87).  In our study, 
we have used these primers to amplify the viral genome directly from the sample. 
Among the 32 samples positive by the real-time PCR-1, only 12 samples were 
amplified by the conventional PCR amplifying VP1-2C region. This can be due to the 
low copy numbers in the clinical samples which are not sufficient to be detected by 
this PCR. Even though this PCR has amplified only CV-A6 and CV-A16 in our study, 
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it has been proven to be able to amplify a wide range of serotypes of enteroviruses, by 
Caro et al (87).  
Recently, HFMD caused by enteroviruses other than EV-71 and CV-A16 have 
become more common world-wide. In our study, among the 12 samples which were 
sequenced, 9 (75%) were found to be CV-A6, which has almost replaced the previous 
common causative agents. This is evidenced by several outbreaks caused by CV-A6 
published by Osterback et al in 2009 in Finland (123), Wei et al in 2011 in Taiwan 
(124), Puenpa et al in 2012 in Thailand (125), and Li et al in 2015 in Beijing, China 
(116). However, a previous study done in our institution by Vijayaraghavan et al 
between 2005 and 2008 identified CV-A16 as the causative agent of two outbreaks in 
Vellore district during that period (25). This shows the changing molecular 
epidemiology of the causative agents of hand foot and mouth disease in Vellore 
district, south India.  
The diagnosis of enterovirus infections relies mainly on the detection of a specific 
target in the genome by RT-PCR, but it requires expensive equipment and people who 
are specially trained, which limits its wide application in the community clinics 
especially in developing countries (126). The detection of the antibody response of the 
patient to the enterovirus infection is easy to perform and rapid, and can be done in 
most of the community health care facilities with standard ELISA equipment. 
However, the use of IgM ELISA for rapid serological diagnosis of enterovirus 
infections has not become a routine practice so far. Boman et al, 1992 used an 
enterovirus-specific indirect ELISA, based on coxsackievirus B-5 as antigen to study 
the IgA, IgM and IgG antibody response to different enterovirus infections, and was 
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found to be reliable for the diagnosis of a recent or current infection by enteroviruses 
(127). A study done by Samuelson et al in Sweden in the year 1990 showed that the 
appearance of IgM antibodies in enteroviral infections is transient, but was found to 
persist in some patients even for 12 months (128). Xu et al developed an IgM-capture 
ELISA specifically for Coxsackievirus A16 infections and found that IgM positivity 
reached 56.3% in the serum samples collected within one day after onset, which 
increased to 95.3% and 100% at 5 to 7 days and after 8 days respectively (126). El-
Hagrassy et al developed a Coxsackievirus B specific IgM ELISA in which the sera of 
24 of 64 (37.5%) patients with acute pericarditis and 14 of 38 (36%) with acute 
myocarditis were positive for Coxsackie-B-virus-specific IgM (129).  
The myocarditis samples in our study which gave higher OD values in the ELISA 
gave negative results in the real-time PCR. This may be due to the inappropriate 
sample (plasma sample) used for the real-time PCR, since endomyocardial biopsy 
tissue is the best sample as per literature (130). However, all the myocarditis patients 
who gave higher OD values were clinically diagnosed as myocarditis, myo-
pericarditis or dilated cardiomyopathy. 
In our study, some of the serum samples from the healthy controls, especially from 
children less than 1 year old also gave high OD values. The control samples were 
collected from the community. This high OD values may be due to the subclinical 
coxsackievirus infections, which is the most common presentation among the 
enterovirus infections (49). In a study published by Wang et al in 2015, the 
seropositivity for anti-CV-A16 and anti- EV71 IgM in children who received health 
examination before admitting to a child care setting, was found to be 4.4% and 1.1% 
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respectively (131). Since the IgM antibodies against coxsackieviruses are present in 
healthy individuals also, as the virus causes a large number of asymptomatic 
infections, this test may not be useful in diagnosing the infection. However, larger 
number of age stratified controls will need to be tested to confirm this. This test can be 
used for the confirmation of the clinical diagnosis when the characteristic symptoms 
and signs of the enterovirus infections are present. This may be particularly useful in 
the diagnosis of enteroviral myocarditis, since the molecular detection of enterovirus 
is difficult in myocarditis (the appropriate sample for PCR is endomyocardial biopsy). 
Limitations of the study  
1. Small number of patients in each study group, which makes the results difficult 
to analyse statistically.  
2. Very few number of serum samples were obtained for both the aseptic 
meningitis and acute haemorrhagic conjunctivitis groups. Hence the results 
could not be analysed. 
3. Due to the low sensitivity of the conventional PCR targeting the VP1-2C 
region of enteroviruses, 20 samples which were positive by the real-time PCR 
could not be sequenced. 
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                                                 CONCLUSION 
The changing molecular epidemiology of the enteroviruses causing HFMD was 
evident from our study. Our study showed that coxsackievirus A6 has started 
replacing the prevalent serotypes causing HFMD previously (CV-A16 and EV-
71) in Vellore district, south India also. 
One of the objectives of our study was to compare two real-time PCRs (EV1 
and EV2) to screen for enteroviruses in the clinical samples, and our study 
showed that EV1 is more sensitive than EV2. Hence, EV1 can be continued as 
the screening PCR for detection of enteroviruses. 
For the molecular typing of enteroviruses, a more sensitive conventional PCR 
need to be used as we were not able to type some of the samples positive by 
real-time PCR. 
Serology can be used as confirmatory test for the diagnosis of clinical infections 
highly suggestive of coxsackievirus as the cause. This may be more useful in 
viral myocarditis due to coxsackievirus since the detection of coxsackieviruses 
by PCR is difficult in myocarditis patients. 
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                                                            ANNEXURES 




Informed Consent form to participate in a research study 
 
 
Study Title: A pilot study on molecular typing and seroepidemiology of human enteroviruses 
(HEV) in aseptic meningitis and some common clinically associated diseases. 
 
 
 
Study Number: ____________ 
Subject’s Initials: __________________ Subject’s Name: _________________________________________ 
Date of Birth / Age: ___________________________ 
(Subject) 
(i) I confirm that I have read and understood the information sheet dated 
  for the above study and have had the opportunity to  ask 
questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am 
free to withdraw at any time, without giving any reason, without my 
medical care or legal rights being affected.[ ] 
(iii) I understand that the Ethics Committee and the regulatory authorities 
will not need my permission to look at my health records both in respect 
of the current study and any further research that may be conducted in 
relation to it, even if I withdraw from the trial. I agree to this access. 
However, I understand that my identity will not be revealed in any 
information released to third parties or published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this 
study provided such a use is only for scientific purpose(s). [ ] 
(v) I agree to take part in the above study. [ ] 
(vi) I hereby give my permission to the investigator(s) to draw 2ml of blood  
            from my vein to use for this study. [ ] 
(vii) I hereby give my permission to take a swab from my lower eyelid/swab 
from the vesicle / draw 4ml blood from my vein for this study.  [  ] 
(viii) I hereby give my permission to draw 2ml of blood from my vein 2 weeks 
after taking the first sample. 
 
 
 
 
 
 
 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Date:  /  /   
Signatory’s Name:    
 
Or 
 
 
 
 
Representative:    
 
Date:  /  /   
 
Signatory’s Name:    
 
 
 
Signature of the Investigator:    
 
Date:  /  /   
 
Study Investigator’s Name:    
 
 
Signature or thumb impression of the Witness:    
 
Date:  /  /   
 
Name & Address of the Witness:    
 
 
 
 
 Informed Consent form for the parent or guardian 
 
Study Title: A pilot study on molecular typing and seroepidemiology of human enteroviruses 
(HEV) in aseptic meningitis and some common clinically associated diseases. 
 
 
 
Study Number: ____________ 
Subject’s Initials: __________________ Subject’s Name: _________________________________________ 
Date of Birth / Age: ___________________________ 
(Subject) 
(i) I confirm that I have read and understood the information sheet dated 
  for the above study and have had the opportunity  to ask 
questions. [ ] 
(ii) I understand that my child’s participation in the study is voluntary and 
that he/she is free to withdraw at any time, without giving any reason, 
without his/her medical care or legal rights being affected.[ ] 
(iii) I understand that the Ethics Committee and the regulatory authorities 
will not need my permission to look at my child’s health records both in 
respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the trial. I agree to 
this access. However, I understand that his /her identity will not be 
revealed in any information released to third parties or published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this 
study provided such a use is only for scientific purpose(s). [ ] 
(v) I agree my child to take part in the above study. [ ] 
(vi) I hereby give my permission to the investigator(s) to draw 2ml of blood 
from my child’s vein to use for this study. 
(vii) I hereby give my permission to use the spinal fluid collected/take a swab 
from my child’s vesicle/take a swab from lower eyelid of my child/draw 
4ml blood from the vein of my child for this study. 
(viii) I hereby give my permission to take an additional 2ml blood from my 
child’s vein  1week/2weeks after taking the first sample. 
 
 
 
 
 
 
Signature (or Thumb impression) of the parent/ guardien 
Date:  /  /   
Signatory’s Name:    
 
Or 
 
 
 
 
 
 
Signature of the Investigator:    
 
Date:  /  /   
 
Study Investigator’s Name:    
 
 
Signature or thumb impression of the Witness:    
 
Date:  /  /   
 
Name & Address of the Witness:    
 
 
 
                                          PATIENT PROFORMA 
STUDY TITLE: A pilot study on molecular typing and seroepidemiology of human enteroviruses 
(HEV) in some common clinically associated diseases. 
 
 
Study number:                                                                                             Date:                           
Name: 
Hospital number: 
Date of birth/age: 
Sex: 
Address:                                                                                                       Mother tongue: 
 
 
 
Date on which symptoms started: 
Aseptic meningitis 
Clinical symptoms:                                                          CSF findings: 
 
 
 
Myocarditis: 
Clinical symptoms:                                                         Echo findings:  
 
 
 
Acute haemorrhagic conjunctivitis  : 
Symptoms:  
 
Hand, foot and mouth disease: 
Clinical symptoms: 
 
 
Clinical diagnosis: 
Date of collection of CSF/Blood/throat swab/vesicular swab/conjunctival swab: 
 
 
 
Date of collection of Blood sample 
                          Acute: 
                          Convalescent: 
Date of Pan-EV PCR: 
Result of Pan- EV PCR:  
Date of conventional PCR: 
Date of Sequencing: 
Serotype identified: 
Date of ELISA: 
 
 
 
 
Name of the person collecting the sample: 
Signature: 
Study no hosp no 
age 
in 
years  
age in 
month
s sex address 
place of 
collection 
date of 
collection EV1  
EV1 
CT EV2 
EV2 
CT 
Conv 
PCR 
result sequence 
HFMD1 842367g 13 0 F West Bengal Derm OPD 
20-05-
2017 N 0 N 0 0 0 
HFMD2 927349F 2 0 M VELLORE DERM OPD 
29-08-
2017 P 19.88  P 23.37 P  
COXSACKIE 
A6 
HFMD3 618271F 4 0 M SAIDAPET DERM OPD 
19-10-
2017 N 0 N 0 0 0 
HFMD4 
509175
G 1 0 F VELLORE DERM OPD 
20-10-
2017 P 29.24 P  32.95 N  0 
HFMD5 
575598
G 1 0 M VELLORE DERM OPD 
26-10-
2017 P 23.72 P 27.96 N  0 
HFMD6 
003821
G 20 0 M VELLORE DERM OPD 
29-10-
2017 P 22.48 P 26.98 P 
COXSACKIE 
A6 
HFMD7 989657F 2 0 M VELLORE DERM OPD 
02-11-
2017 P 26.01 P 30.06 N  0 
HFMD8 
988034
G 3 0 F WEST BENGAL DERM OPD 
03-11-
2017 N 0 N 0 0 
 
HFMD9 
842820
G 26 0 M VELLORE DERM OPD 
03-11-
2017 P 24.61 P 29.57 P 
COXSACKIE 
A6 
HFMD10 247291C 14 0 M VELLORE DERM OPD 
04-11-
2017 P 20.29 P 23.25 P 
COXSACKIE 
A6 
HFMD11 
529921
G 1 0 F CUDDALORE Q5N WARD 
08-11-
2017 P 26.25 P 28.55 P 
COXSACKIE 
A6 
HFMD12 
056033
D 27 0 M VELLORE DERM OPD 
09-11-
2017 P 18.91 P 21.92 P 
COXSACKIE 
A6 
HFMD13 
575928
G 0 8 M VELLORE DERM OPD 
14-11-
2017 P 35.11 N 0 0 
 
HFMD14 
556867
G 0 9 M VELLORE DERM OPD 
18-11-
2017 P 29.29 P 31.02 0 
 HFMD15 552726 0 8 M VELLORE DERM OPD 21-11- P 29.37 P 31.25 0 
 
G 2017 
HFMD16 
555847
G 0 7 M VELLORE DERM OPD 
22-11-
2017 P 26.48 P 27.61 0 
 
HFMD17 
430925
G 9 0 M BANGLADESH HAEMAT OPD 
27-11-
2017 P 31.13 P 32.67 0 
 
HFMD18 
553185
G 0 8 M VELLORE DERM OPD 
05-12-
2017 P 25.87 P 30.38 0 
 
HFMD19 
519993
G 1 0 F VELLORE DERM OPD 
06-12-
2017 P 24.73 P 29.95 0 
 
HFMD20 
519994
G 1 0 M VELLORE DERM OPD 
06-12-
2017 P 25.89 P 31.1 0 
 
HFMD21 951764F 2 0 F VELLORE DERM OPD 
07-12-
2017 P 25.79 P 31.2 0 
 
HFMD22 
961659
G 2 0 F BENGALURU Q5N WARD 
08-12-
2017 P 20.88 P 23.23 P 
COXSACKIE 
A6 
HFMD23 
538729
G 0 10 F VELLORE DERM OPD 
11-12-
2017 P 27.15 P 31.17 0 
 
HFMD24 
070913
H 1 0 F VELLORE DERM OPD 
11-12-
2017 P 17.82 P 21.15 P 
COXSACKIE 
A6 
HFMD25 
109105
G 2 0 F VELLORE DERM OPD 
12-12-
2017 P 16.22 P 21.92 P 
COXSACKIE 
A6 
HFMD26 299236B 22 0 M VELLORE DERM OPD 
13-12-
2017 P 25.03 P 27.5 P 
COXSACKIE 
A16 
HFMD27 692408B 18 0 M VELLORE DERM OPD 
23-12-
2017 N 0 N 0 0 
 
HFMD28 
084828
H 1 
 
M 
THIRUCHIRAPALL
I DERM OPD 
27-12-
2017 P 28.46 P 31.37 0 
 
HFMD29 
516395
G 1 0 M VELLORE DERM OPD 
15-01-
2018 P 20.77 P 23.47 P 
COXSACKIE 
A16 
HFMD30 
538346
G 1 0 M CHITTOOR DERM OPD 
12-05-
2018 P 25.8 P 32.43 0 
 HFMD31 568612 1 0 F CHITTOOR DERM OPD 13-05- P 
 
P 
 
P COXSACKIE 
G 2018 A16 
C1 350776F 6 0 M CHITTOOR Q5S WARD 
07-06-
2017 P 34.99 N 0 0 0 
C2 
561997
G 3 0 M CHETPET Q5S WARD 
20-06-
2017 N 0 N 0 0 0 
C3 
930987
G 5 0 M JHARKHAND Q5S WARD 
23-07-
2017 N 0 N 0 0 0 
C4 
787953
G 1 0 M CHITTOOR PCAS 
24-09-
2017 N 0 N 0 0 0 
C5 
571432
G 0 9 M VELLORE PCAS 
23-10-
2017 N 0 N 0 0 0 
C6 
571938
G 0 1 M VELLORE PCAS 
23-10-
2017 P 32.26 N 0 0 0 
C7 
592106
G 1 0 M VELLORE PCAS 
15-02-
2017 N 0 N 0 
  
C8 
592399
G 14 0 M VELLORE PCAS 
27-02-
2018 N 0 N 0 0 0 
C9 
592447
G 3 0 F VELLORE PCAS 
04-03-
2018 N 0 N 0 0 0 
C10 
592325
G 14 0 F VELLORE PCAS 
09-03-
2018 P 33.6 N 0 0 0 
C11 
596810
G 0 4 M VELLORE Q5S WARD 
13-03-
2018 N 0 N 0 0 0 
C12 
147142
H 14 0 M WEST BENGAL PCAS 
13-03-
2018 N 0 N 0 0 0 
C13 
590262
G 0 9 F VELLORE PCAS 
19-03-
2018 N 0 N 0 0 0 
C14 
529617
G 1 0 F VELLORE PCAS 
21-03-
2018 N 0 N 0 0 0 
C15 
533225
G 1 0 M VELLORE PCAS 
24-03-
2018 N 0 N 0 0 0 
C16 592734 0 6 M VELLORE PCAS 26-03- N 0 N 0 0 0 
G 2018 
C17 
595125
G 0 7 M THIRUVALLUR Q5S WARD 
26-03-
2018 N 0 N 0 0 0 
C18 
592931
G 0 6 M CHITTOOR PCAS 
05-04-
2018 N 0 N 0 0 0 
C19 
593000
G 2 0 M VELLORE PCAS 
10-04-
2018 N 0 N 0 0 0 
C20 
592986
G 6 0 F VELLORE PCAS 
10-04-
2018 N 0 N 0 0 0 
C21 
595564
G 0 8 M VELLORE PCAS 
16-04-
2018 N 0 N 0 0 0 
C22 
182118
H 7 0 M VELLORE PCAS 
26-04-
2018 N 0 N 0 0 0 
C23 485078F 4 0 F VELLORE PCAS 
26-04-
2018 N 0 N 0 0 0 
C24 
182653
H 0 8 M CHITTOOR PCAS 
27-04-
2018 N 0 N 0 0 0 
C25 
200251
H 1 0 F VELLORE PCAS 
28-04-
2018 P 34.97 N 0 0 0 
C26 
590085
G 0 9 M VELLORE PCAS 
08-05-
2018 N 0 N 0 0 0 
MC1 956325F 2 0 F VELLORE Q5S WARD 
24-07-
2017 N 0 N 0 0 0 
MC2 
569602
G 0 4 F POLUR PICU 
25-08-
2017 N 0 N 0 0 0 
MC3 
915739
G 21 0 M KERALA BMTU 
05-10-
2017 N 0 N 0 0 0 
MC4 
500632
G 57 0 M KERALA BMTU 
17-10-
2017 N 0 N 0 0 0 
MC5 
575685
G 2 0 M THIRUVALLUR PICU 
02-11-
2017 N 0 N 0 0 0 
MC6 838660 26 0 M BANGLADESH BMTU 13-11- N 0 N 0 0 0 
G 2017 
MC7 
856010
G 10 0 F KERALA AICU 
 
N 0 N 0 0 0 
MC8 
568004
G 0 5 F VELLORE PICU 
 
N 0 N 0 0 0 
MC9 
592206
G 0 7 F VELLORE PICU 
 
N 0 N 0 0 0 
MC10 
196400
D 10 0 F VELLORE PICU 
05-03-
2018 N 0 N 0 0 0 
MC11 
571977
G 0 7 
 
THIRUVALLUR PICU 
29-03-
2018 N 0 N 0 0 0 
MC12 
022405
H 47 0 M ASSAM AICU 
02-04-
2018 N 0 N 0 0 0 
MC13 
589281
G 40 0 F VELLORE M WARD 
 
N 0 N 0 0 0 
MC14 550604F 0 2 F CHITTOOR PICU 
 
N 0 N 0 0 0 
MC15 
200936
H 0 1 F CHITTOOR PHDU 
05-07-
2018 N 0 N 0 0 0 
MC16 
200984
H 7 0 M CHITTOOR PHDU 
05-07-
2018 N 0 N 0 0 0 
MC17 
200981
H 0 1 M HOSUR PHDU 
05-07-
2018 N 0 N 0 0 0 
MC18 
200966
H 4 0 M VELLORE 
 
06-07-
2018 N 0 N 0 0 0 
PF1 
856010
G 10 0 F KERALA AICU 
 
0 0 0 0 0 0 
PF2 
022405
H 47 0 M ASSAM AICU 
02-04-
2018 N 0 N 0 0 0 
AHC1 593577S 84 0 M KERALA OPH OPD 
03-08-
2017 N 0 N 0 0 0 
AHC2 595217S 37 0 F VELLORE OPH OPD 
14-08-
2017 N 0 N 0 0 0 
AHC3 597064S 50 0 F VELLORE OPH OPD 
28-08-
2017 P 36.52 N 0 0 0 
AHC4 614127S 30 0 F VELLORE OPH OPD 
09-10-
2017 N 0 N 0 0 0 
 
